Drugs / Semaglutide
Semaglutide
Regulatory milestones approvals, filings & regulatory actions · 26 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed obesity disorder 5 milestones | |||||
| Filed | US (FDA) | Wegovy | obesity disorder | 2025-11-26 | “announced the submission of a sNDA to the U.S. Food and Drug Administration (FDA) for a higher dose of semaglutide injection 7.2 mg” novonordisk.com ↗ “Wegovy® 7.2 mg FDA NDA filing” novonordisk.com ↗ |
| Filed | EU (EMA) | Wegovy | obesity disorder | 2025-08-06 | “semaglutide 7.2 mg (a higher dose of Wegovy®) has been submitted to the EU regulatory authorities.” novonordisk.com ↗ |
| Filed | US (FDA) | — | obesity disorder | 2025-05-07 | “once-weekly semaglutide 2.4 mg in MASH was submitted for regulatory approval in both the EU and US” novonordisk.com ↗ “oral semaglutide 25 mg in obesity was submitted for regulatory review to the US FDA.” novonordisk.com ↗ |
| Filed | EU (EMA) | — | obesity disorder | 2020-12-18 | “submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for subcutaneous semaglutide 2.4 mg” novonordisk.com ↗ “submitted oral semaglutide 25 mg once-daily for obesity to the European Medicines Agency (EMA)” novonordisk.com ↗ |
| Filed | US (FDA) | — | obesity disorder | 2020-12-04 | “submission of a new drug application (NDA) to the US Food and Drug Administration (FDA) for subcutaneous semaglutide 2.4 mg” novonordisk.com ↗ |
| Filed type 2 diabetes mellitus 7 milestones | |||||
| Rejected (CRL) | US (FDA) | — | type 2 diabetes mellitus | 2021-03-22 | “FDA has issued a Refusal to File letter covering the label expansion application for once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes” novonordisk.com ↗ |
| Filed | US (FDA) | Ozempic® | type 2 diabetes mellitus | 2021-01-20 | “submission of a label expansion application to the US Food and Drug Administration (FDA) for the existing marketing authorisation for Ozempic®” novonordisk.com ↗ |
| Filed | EU (EMA) | Ozempic® | type 2 diabetes mellitus | 2020-12-29 | “Der er indsendt registreringsansøgning for Ozempic® til flere regulatoriske myndigheder, herunder Det Europæiske Lægemiddelagentur og de japanske sundhedsmyndigheder.” novonordisk.com ↗ “submission of a label extension application to the European Medicines Agency (EMA) for the existing marketing authorisation for Ozempic®” novonordisk.com ↗ |
| Filed | EU (EMA) | — | type 2 diabetes mellitus | 2019-04-26 | “submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for oral semaglutide” novonordisk.com ↗ “oral semaglutide has been filed for regulatory approval of glycaemic control in both the USA and the EU.” novonordisk.com ↗ |
| Filed | Other | — | type 2 diabetes mellitus | 2019-04-26 | “Oral semaglutide has now been submitted for regulatory approval in the US, the EU and Canada.” novonordisk.com ↗ |
| Filed | US (FDA) | Ozempic | type 2 diabetes mellitus | 2019-03-20 | “Earlier this year, Novo Nordisk filed a supplemental drug application for Ozempic® (semaglutide) tablets 25 mg for use in adults with type 2 diabetes.” novonordisk-us.com ↗ “A second NDA was submitted for oral semaglutide seeking approval for a cardiovascular (CV) risk reduction indication in adults with type 2 diabetes.” novonordisk.com ↗ “An NDA was submitted for oral semaglutide seeking approval for an indication for the treatment of adults with type 2 diabetes.” novonordisk.com ↗ “Finally, an sNDA was submitted for Ozempic® for a cardiovascular risk reduction indication in adults with type 2 diabetes.” novonordisk.com ↗ “oral semaglutide has been filed for regulatory approval of glycaemic control in both the USA and the EU.” novonordisk.com ↗ “oral semaglutide and Ozempic® have been filed for regulatory approval for CV risk reduction in the USA.” novonordisk.com ↗ |
| Filed | Japan (PMDA) | Ozempic® | type 2 diabetes mellitus | 2017-02-28 | “Der er indsendt registreringsansøgning for Ozempic® til flere regulatoriske myndigheder, herunder Det Europæiske Lægemiddelagentur og de japanske sundhedsmyndigheder.” novonordisk.com ↗ “submission of a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare for semaglutide” novonordisk.com ↗ |
| Approved Indication not stated 6 milestones | |||||
| Filed | US (FDA) | — | — | 2026-06-07 | “Novo Nordisk filed a New Drug Application with the U.S.” novonordisk.com ↗ |
| Label expansions (6) | US (FDA) | WEGOVY | — | 2022-12-23 – 2026-03-19 | fda.gov ↗ |
| Label expansions (4) | US (FDA) | OZEMPIC | — | 2020-01-16 – 2025-10-17 | fda.gov ↗ |
| Filed | EU (EMA) | — | MASH | 2025-05-07 | “once-weekly semaglutide 2.4 mg in MASH was submitted for regulatory approval in both the EU and US” novonordisk.com ↗ |
| Approved | EU (EMA) | Ozempic | — | 2018-02-08 | europa.eu ↗ |
| Approved | US (FDA) | OZEMPIC | — | 2017-12-05 | fda.gov ↗ |
Trials 393 · started per year
today
US approved 2017
EU approved 2018
1
1
4
1
2
7
19
3
12
11
16
28
10
33
38
47
48
48
57
6
1
200720082009201020112012201320142015201620172018201920202021202220232024202520262027202820292030
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 04 trials | ||||||
| Phase 0 | NCT07627191 | Oct 2026 → Jun 2028 expected | colorectal cancer, hepatocellular carcinoma, malignant pancreatic neoplasm | University of Arizona | Recruiting | No outcome recorded |
| Phase 0 | NCT06807970 | Sep 2025 → Jul 2027 expected | osteoarthritis, knee | The University of Hong Kong | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06338553 | Jun 2024 → Mar 2027 expected | type 1 diabetes mellitus | Vanderbilt University Medical Center | Recruiting | No outcome recorded |
| Phase 0 | NCT05249881 | Mar → Dec 2022 | type 2 diabetes mellitus | Aga Khan University | Unknown | No outcome recorded |
| Phase 193 trials · 8 met primary · 3 missed | ||||||
| Phase 1 | NCT07840729 | Oct 2026 → Feb 2027 expected | — | Shanghai JMT-Bio Inc. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07855133 | Sep 2026 → Sep 2028 expected | obesity disorder, type 2 diabetes mellitus | Novo Nordisk A/S | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07845578 | Sep 2026 → Sep 2027 expected | obesity disorder | Novo Nordisk A/S | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07527195 | Apr 2026 → Apr 2028 expected | obesity disorder | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 1 | NCT07223983 | Mar 2026 → Feb 2027 expected | alcohol-related disorders | Yale University | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06222437 | Feb 2026 | polycystic ovary syndrome | Methodist Health System | Withdrawn | No outcome recorded |
| Phase 1 | NCT07225816 | Nov 2025 → Jun 2026 overdue | obesity disorder | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 1 | NCT07010432 | Jun 2025 → May 2028 expected | obesity disorder | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 1 | NCT06648031 | Dec 2024 → Jul 2025 | type 2 diabetes mellitus | Lexaria Bioscience Corp. | Completed | No outcome recorded |
| Phase 1 | NCT06716307 | Dec 2024 → Mar 2025 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT05202353 | Nov 2024 → Jan 2027 expected | obesity disorder | Boehringer Ingelheim | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06642584 | Oct 2024 → Jul 2025 | — | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT06575738 | Oct 2024 → Sep 2027 expected | obesity disorder | University of Colorado, Denver | Recruiting | No outcome recorded |
| Phase 1 | NCT06446531 | Sep 2024 → Jul 2027 expected | cardiovascular disorder, prediabetes syndrome | The University of Texas Health Science Center at San Antonio | Recruiting | No outcome recorded |
| Phase 1 | NCT06422624 | Aug → Nov 2024 | type 2 diabetes mellitus | Bostal Drug Delivery Co., Ltd | Unknown | No outcome recorded |
| Phase 1 | NCT06403761 | May 2024 → Dec 2025 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT06149260 | Feb → Aug 2024 | systemic sclerosis | Second Xiangya Hospital of Central South University | Unknown | No outcome recorded |
| Phase 1 | NCT06289504 | Feb → Oct 2024 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT06207877 | Feb → Oct 2024 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT06267092 | Feb 2024 → Apr 2025 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT06699329 | Jan → May 2024 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT06097390 | Sep 2023 → Feb 2024 | — | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT05996874 | Aug 2023 → Apr 2024 | — | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT05751226 | Apr 2023 → Aug 2024 | obesity disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT05784402 | Mar 2023 → Feb 2024 | — | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT05766709 | Mar 2023 → Jan 2024 | metabolic dysfunction-associated steatohepatitis | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT05671653 | Jan → Nov 2023 | obesity disorder | Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT05689099 | Jan → May 2023 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT05498610 | Aug → Oct 2022 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT05429593 | Jun 2022 → Mar 2023 | — | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT05435677 | Jun 2022 → Apr 2023 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT05071898 | Apr 2022 → Nov 2026 expected | obesity disorder, type 2 diabetes mellitus | University of Maryland, Baltimore | Recruiting | No outcome recorded |
| Phase 1 | NCT05236517 | Feb → Sep 2022 | obesity disorder | Novo Nordisk A/S | Completed | Met primary |
| Phase 1 | NCT05227196 | Feb 2022 → Jun 2023 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | Met primary |
| Phase 1 | NCT05232708 | Jan → Aug 2022 | diabetes mellitus, noninsulin-dependent, 2 | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT05153564 | Dec 2021 → Aug 2022 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT05129891 | Nov 2021 → Feb 2023 | low density lipoprotein cholesterol, mild elevation of, type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT04817644 | Sep 2021 → May 2023 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT04940078 | Jul 2021 → Jan 2022 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT04878406 | May → Jul 2021 | — | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT04779697 | Feb 2021 → Nov 2024 | obesity disorder | Yale University | Completed | Mixed |
| Phase 1 | NCT04524832 | Sep 2020 → Feb 2022 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT04513704 | Aug 2020 → Apr 2021 | — | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT04259801 | Feb 2020 → Mar 2022 | obesity disorder, type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT04238962 | Feb → Oct 2020 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT04152915 | Nov 2019 → May 2020 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT04016974 | Oct 2019 → Jan 2021 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT04109508 | Oct 2019 → Dec 2020 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT04097600 | Sep 2019 → Dec 2020 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT04032197 | Aug 2019 → Dec 2022 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | Missed primary |
| Phase 1 | NCT04012255 | Jul → Aug 2019 | obesity disorder | Novo Nordisk A/S | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT03842202 | Feb → Nov 2019 | obesity disorder | Novo Nordisk A/S | Completed | Met primary |
| Phase 1 | NCT03789578 | Jan → Oct 2019 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT03707990 | Oct 2018 → Aug 2019 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT03611322 | Aug 2018 → Jan 2019 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT03600480 | Jul 2018 → Jun 2020 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT03598621 | Jul 2018 → Jan 2019 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT03574584 | Jun 2018 → Jul 2019 | metabolic disease, obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT03466567 | Mar → Jul 2018 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT03357380 | Nov 2017 → Mar 2020 | NAFLD1 | Novo Nordisk A/S | Completed | Missed primary |
| Phase 1 | NCT03288740 | Sep 2017 → Jul 2018 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT03010475 | Jan → Jun 2017 | diabetes mellitus | Novo Nordisk A/S | Completed | Missed primary |
| Phase 1 | NCT02920385 | Oct 2016 → Apr 2017 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02877355 | Aug 2016 → Nov 2017 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02845219 | Jul → Dec 2016 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02773381 | Jun 2016 → Oct 2018 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02557620 | Sep 2015 → Apr 2016 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02249871 | Sep 2014 → Apr 2015 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02249910 | Sep 2014 → Mar 2015 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02243098 | Sep 2014 → Apr 2015 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | Met primary |
| Phase 1 | NCT02231684 | Sep 2014 → Jan 2015 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02212067 | Aug 2014 → May 2015 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | Met primary |
| Phase 1 | NCT02210871 | Aug 2014 → Jun 2015 | liver disorder, type 2 diabetes mellitus | Novo Nordisk A/S | Completed | Met primary |
| Phase 1 | NCT02161588 | Jun → Nov 2014 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02172313 | Jun → Oct 2014 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02146079 | May → Oct 2014 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02147431 | May 2014 → May 2015 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02079870 | Mar 2014 → Jan 2015 | diabetes mellitus, obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02070510 | Feb → Aug 2014 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02064348 | Feb 2014 → Apr 2015 | diabetes mellitus | Novo Nordisk A/S | Completed | Met primary |
| Phase 1 | NCT02060266 | Feb → Apr 2014 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02022254 | Dec 2013 → Aug 2014 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | Met primary |
| Phase 1 | NCT02016911 | Dec 2013 → Jan 2015 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02014259 | Dec 2013 → Oct 2014 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01866748 | May 2013 → Apr 2014 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01686945 | Sep 2012 → Apr 2013 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01572753 | Apr → Sep 2012 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01324505 | Mar 2011 → Jan 2012 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01037582 | Dec 2009 → May 2010 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT00833716 | Feb 2009 → Jul 2010 | impaired renal function disease, type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT00851773 | Feb → Oct 2009 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT00813020 | Jan → Apr 2009 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT03144271 | Jun → Oct 2007 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1/27 trials · 1 missed | ||||||
| Phase 1/2 | NCT07642635 | Sep 2026 → Sep 2030 expected | Duchenne muscular dystrophy | Vanderbilt University Medical Center | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07563699 | Jul 2026 → Apr 2028 expected | type 2 diabetes mellitus | Mapi Pharma Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07374328 | Jun 2025 → May 2026 overdue | type 2 diabetes mellitus | Second Affiliated Hospital of Guangzhou Medical University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06541509 | Jul 2024 → Jul 2025 overdue | heart failure, obesity disorder | University Medical Centre Ljubljana | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05746039 | Jan 2024 → Dec 2027 expected | chronic obstructive pulmonary disease, obesity disorder, pulmonary hypertension, pulmonary sarcoidosis | University of Pennsylvania | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07336862 | Jan 2024 → Dec 2027 expected | obesity disorder | China-Japan Friendship Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04702516 | Mar 2021 → Aug 2022 | — | Morten Frost | Unknown | Missed primary |
| Phase 270 trials · 10 met primary · 6 missed | ||||||
| Phase 2 | NCT07430332 | Sep 2027 → Jun 2029 expected | type 1 diabetes mellitus | Children's Hospital Medical Center, Cincinnati | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07614412 | Jan 2027 → Jan 2028 expected | type 1 diabetes mellitus | Ministry of Health, Saudi Arabia | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07820358 | Jan 2027 → Dec 2028 expected | atypical endometrial hyperplasia, endometrial cancer, obesity disorder, stage I endometrioid carcinoma | The Methodist Hospital Research Institute | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07249554 | Nov 2026 → Jul 2028 expected | alcohol-related disorders | Johns Hopkins University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07511543 | Oct 2026 → Oct 2028 expected | ischemic stroke | Population Health Research Institute | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06073184 | Sep 2026 → Feb 2029 expected | atypical endometrial hyperplasia, endometrial cancer | GynOncTrials | Recruiting | No outcome recorded |
| Phase 2 | NCT07509112 | Sep 2026 → Jan 2027 expected | methamphetamine dependence | Kirby Institute | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07357740 | Aug 2026 → Aug 2027 | type 2 diabetes mellitus | Novo Nordisk A/S | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT07639021 | Jun 2026 → Jun 2027 expected | obesity disorder | Novo Nordisk A/S | Active not recruiting | No outcome recorded |
| Phase 2 | NCT07282769 | Jun 2026 → Feb 2027 expected | trichotillomania | University of Chicago | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07179120 | May → Aug 2026 overdue | male infertility | First Affiliated Hospital of Wenzhou Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07523633 | Apr 2026 → Apr 2028 expected | cannabis dependence, substance abuse | Anders Fink-Jensen, MD, DMSci | Recruiting | No outcome recorded |
| Phase 2 | NCT07221214 | Apr 2026 → Oct 2029 expected | HIV infectious disease, alcohol-related disorders, cardiovascular disorder | Vanderbilt University Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT07107334 | Apr 2026 → Nov 2028 expected | endometrial endometrioid adenocarcinoma | University of Florida | Recruiting | No outcome recorded |
| Phase 2 | NCT07314528 | Apr 2026 → Sep 2028 expected | obesity disorder, rectal cancer | St. James's Hospital, Ireland | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07204249 | Feb 2026 → Feb 2030 expected | methamphetamine dependence | San Francisco Department of Public Health | Recruiting | No outcome recorded |
| Phase 2 | NCT07325500 | Feb 2026 → May 2028 expected | — | The University of Texas Health Science Center, Houston | Recruiting | No outcome recorded |
| Phase 2 | NCT07202247 | Jan 2026 → Apr 2028 expected | prostate carcinoma | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT07227948 | Jan 2026 → Jan 2029 expected | substance-related disorder | The University of Texas Health Science Center, Houston | Recruiting | No outcome recorded |
| Phase 2 | NCT07040592 | Jan 2026 → Jun 2027 expected | HIV infectious disease, alcohol-related disorders | Yale University | Recruiting | No outcome recorded |
| Phase 2 | NCT07135245 | Jan 2026 → Sep 2030 expected | Alzheimer disease | Rune Skovgaard Rasmussen | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07200622 | Sep 2025 → Dec 2027 expected | Alzheimer disease | Imperial College London | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06691243 | Aug 2025 → Jan 2027 expected | HIV infectious disease, substance-related disorder | University of Maryland, Baltimore | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06639464 | Jun 2025 → Aug 2026 overdue | opiate dependence | Brigham and Women's Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07610174 | Jun 2025 → Apr 2026 | cardiac valvular defect, heart failure | Kafrelsheikh University | Completed | No outcome recorded |
| Phase 2 | NCT05829460 | Mar 2025 → Apr 2030 | endometrial disorder | Washington University School of Medicine | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT07819227 | Feb 2025 → Aug 2026 | chronic kidney disease | University Medical Center Groningen | Completed | No outcome recorded |
| Phase 2 | NCT06548490 | Jan 2025 → Nov 2026 expected | drug-induced mental disorder, opiate dependence | Milton S. Hershey Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT06411210 | Jul 2024 → Apr 2028 expected | obesity disorder, type 1 diabetes mellitus | Yale University | Recruiting | No outcome recorded |
| Phase 2 | NCT06050577 | Jun 2024 → Jan 2027 expected | type 2 diabetes mellitus | Odense University Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06409130 | May 2024 → Nov 2025 | alcoholic liver disease | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 2 | NCT06173778 | Apr 2024 → May 2028 expected | obesity disorder | The University of Texas Health Science Center, Houston | Recruiting | No outcome recorded |
| Phase 2 | NCT05822609 | Apr 2024 → Jun 2027 expected | diabetic kidney disease, type 1 diabetes mellitus | University of Washington | Recruiting | No outcome recorded |
| Phase 2 | NCT06131372 | Apr 2024 → Sep 2025 | chronic kidney disease, obesity disorder, type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 2 | NCT05424003 | Feb 2024 → Aug 2026 overdue | fatty liver disease | University of Virginia | Recruiting | No outcome recorded |
| Phase 2 | NCT06072963 | Jan 2024 → Dec 2027 expected | Alzheimer disease, cognitive impairment with or without cerebellar ataxia, metabolic syndrome X | Rutgers, The State University of New Jersey | Recruiting | No outcome recorded |
| Phase 2 | NCT05938712 | Oct 2023 → Oct 2027 expected | disease related to solid organ transplantation | University Health Network, Toronto | Recruiting | No outcome recorded |
| Phase 2 | NCT06015893 | Oct 2023 → Mar 2027 expected | alcohol-related disorders, substance dependence | National Institute on Drug Abuse (NIDA) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06974825 | Aug 2023 → Aug 2024 | type 2 diabetes mellitus | BrightGene Bio-Medical Technology Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT05897372 | Aug 2023 → Sep 2024 | diabetic kidney disease | Iain Bressendorff | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT06005012 | Jul 2023 → Dec 2026 expected | NAFLD1, fibrotic liver disease, type 2 diabetes mellitus | University of California, San Diego | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05067621 | Jul 2023 → Dec 2026 expected | NAFLD1, glucose intolerance, obesity disorder, type 2 diabetes mellitus | Yale University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05891587 | Jul 2023 → Jul 2025 | alcohol-related disorders | Oklahoma State University Center for Health Sciences | Completed | No outcome recorded |
| Phase 2 | NCT05895643 | Jun 2023 → Jul 2025 | alcohol abuse, alcohol dependence | Psychiatric Centre Rigshospitalet | Completed | Met primary |
| Phase 2 | NCT05537233 | Apr 2023 → Aug 2024 | obesity disorder, type 1 diabetes mellitus | Viral N. Shah | Completed | Met primary |
| Phase 2 | NCT05616013 | Nov 2022 → May 2024 | obesity disorder | Eli Lilly and Company | Completed | Met primary |
| Phase 2 | NCT05254314 | Oct 2022 → Sep 2026 overdue | asthma | Vanderbilt University Medical Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05530577 | Oct 2022 → May 2024 | nicotine dependence | University of North Carolina, Chapel Hill | Completed | Missed primary |
| Phase 2 | NCT05520775 | Sep 2022 → Apr 2024 | alcohol-related disorders | University of North Carolina, Chapel Hill | Completed | Met primary |
| Phase 2 | NCT05302596 | Sep 2022 → Oct 2023 | obesity disorder | State University of New York at Buffalo | Completed | No outcome recorded |
| Phase 2 | NCT05486065 | Aug 2022 → Oct 2023 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | Met primary |
| Phase 2 | NCT05356104 | May 2022 → May 2027 expected | cerebrovascular disorder | Chinese University of Hong Kong | Recruiting | No outcome recorded |
| Phase 2 | NCT05173714 | Dec 2021 → Dec 2026 expected | chronic kidney disease, obesity disorder | Srinvasan Beddhu | Recruiting | No outcome recorded |
| Phase 2 | NCT05144984 | Nov 2021 → Feb 2023 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | Met primary |
| Phase 2 | NCT04466345 | Oct 2021 → Dec 2024 | major depressive disorder | University Health Network, Toronto | Completed | Missed primary |
| Phase 2 | NCT04615871 | Sep 2021 → Mar 2022 | COVID-19 | Vladimír Džavík | Unknown | No outcome recorded |
| Phase 2 | NCT05016882 | Aug 2021 → Dec 2024 | metabolic dysfunction-associated steatohepatitis | Novo Nordisk A/S | Completed | Missed primary |
| Phase 2 | NCT04971785 | Aug 2021 → Nov 2024 | metabolic dysfunction-associated steatohepatitis | Gilead Sciences | Completed | Missed primary |
| Phase 2 | NCT04982575 | Aug 2021 → Jul 2022 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | Missed primary |
| Phase 2 | NCT04216589 | Feb 2021 → Mar 2023 | HIV infectious disease, NAFLD1 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT04143945 | Oct 2019 → Jan 2020 | obesity and hypopigmentation, type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 2 | NCT03987074 | Jul 2019 → Jul 2020 | metabolic dysfunction-associated steatohepatitis | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT03884075 | Jul 2019 → Aug 2026 overdue | NAFLD1, metabolic dysfunction-associated steatohepatitis | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Recruiting | No outcome recorded |
| Phase 2 | NCT04007107 | Jun → Jul 2019 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 2 | NCT03987451 | Jun 2019 → Apr 2021 | metabolic dysfunction-associated steatohepatitis | Novo Nordisk A/S | Completed | Missed primary |
| Phase 2 | NCT04019197 | May 2019 → Apr 2024 overdue | HIV infectious disease, localized lipodystrophy, obesity disorder | Case Western Reserve University | Active not recruiting | Mixed |
| Phase 2 | NCT02970942 | Nov 2016 → Feb 2020 | metabolic dysfunction-associated steatohepatitis | Novo Nordisk A/S | Completed | Met primary |
| Phase 2 | NCT02453711 | Oct 2015 → Mar 2017 | metabolic disease, obesity disorder | Novo Nordisk A/S | Completed | Met primary |
| Phase 2 | NCT02461589 | Sep 2015 → Oct 2016 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | Met primary |
| Phase 2 | NCT00696657 | Jun 2008 → Feb 2009 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | Met primary |
| Phase 2/310 trials · 1 met primary | ||||||
| Phase 2/3 | NCT07797036 | Sep 2027 → Sep 2030 expected | gestational diabetes, metabolic syndrome X | University of Massachusetts, Worcester | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT06913023 | Sep 2026 → Jun 2029 expected | — | University Health Network, Toronto | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07223242 | Feb 2025 → Dec 2026 expected | cardiomyopathy, heart failure | University of Texas Southwestern Medical Center | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06896981 | Jan → Oct 2025 | obesity disorder, polycystic ovary syndrome | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Completed | No outcome recorded |
| Phase 2/3 | NCT06387199 | Dec 2024 → Jan 2027 expected | type 1 diabetes mellitus | McGill University Health Centre/Research Institute of the McGill University Health Centre | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06423599 | Apr 2024 → Dec 2027 expected | heart failure, obesity disorder | Jens D Hove, MD,PHD | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05788965 | Oct 2023 → Dec 2024 | cystic fibrosis, cystic fibrosis-related diabetes | University of Minnesota | Completed | No outcome recorded |
| Phase 2/3 | NCT05205928 | Oct 2022 → Apr 2024 | type 1 diabetes mellitus | McGill University Health Centre/Research Institute of the McGill University Health Centre | Completed | Met primary |
| Phase 2/3 | NCT03919929 | May 2019 → Oct 2023 | NAFLD1, polycystic ovary syndrome | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 2/3 | NCT03899402 | May 2019 → Jan 2026 overdue | type 1 diabetes mellitus | State University of New York at Buffalo | Active not recruiting | No outcome recorded |
| Phase 3112 trials · 55 met primary · 3 missed | ||||||
| Phase 3 | NCT07845994 | Nov 2026 → Feb 2031 expected | craniopharyngioma | University Hospital, Angers | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07817251 | Sep 2026 → Jun 2027 expected | type 2 diabetes mellitus | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 3 | NCT06934655 | Sep 2026 → Nov 2030 expected | — | Children's Hospital Los Angeles | Recruiting | No outcome recorded |
| Phase 3 | NCT07770841 | Aug 2026 → Feb 2028 expected | obesity disorder | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 3 | NCT07218354 | Jul 2026 → Mar 2029 expected | alcohol-related disorders | VA Office of Research and Development | Recruiting | No outcome recorded |
| Phase 3 | NCT07357766 | Jun 2026 → Nov 2027 | obesity disorder | Novo Nordisk A/S | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT07021937 | Jun 2026 → Apr 2031 expected | obesity and hypopigmentation | University of Colorado, Denver | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07581145 | Apr 2026 → Dec 2028 expected | ulcer of lower limbs | Bispebjerg Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT07428746 | Apr 2026 → Nov 2028 expected | type 2 diabetes mellitus | Emory University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07059377 | Feb → Dec 2026 expected | nicotine dependence, type 2 diabetes mellitus | Ottawa Heart Institute Research Corporation | Recruiting | No outcome recorded |
| Show all 112 trials opens the full record — a long page | ||||||
| Phase 466 trials · 3 met primary | ||||||
| Phase 4 | NCT07858331 | Jan 2027 → Jan 2029 expected | chronic kidney disease, obesity disorder | Kristin Clemens | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07462663 | Jan 2027 → Apr 2031 expected | atypical endometrial hyperplasia, endometrial cancer, intraepithelial neoplasia, morbid obesity | Hospital Universitari de Bellvitge | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07027969 | Nov 2026 → Dec 2029 expected | atrial fibrillation, obesity disorder | Ali Aminian | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06977438 | Oct 2026 → Jan 2031 expected | obesity disorder | University of Minnesota | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07389941 | Oct 2026 → Apr 2029 expected | atrial fibrillation | University of Luebeck | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07617155 | Sep 2026 → Sep 2028 expected | acute pancreatitis, hypertriglyceridemia, recurrent acute pancreatitis | Peking Union Medical College Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07592546 | Aug 2026 → Dec 2028 expected | morbid obesity | Alain Dagher | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07485062 | May 2026 → May 2029 expected | subjective cognitive decline, type 2 diabetes mellitus | Western University, Canada | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07558863 | Apr 2026 → Mar 2028 expected | diabetic autonomic neuropathy, type 2 diabetes mellitus | The First Affiliated Hospital with Nanjing Medical University | Recruiting | No outcome recorded |
| Phase 4 | NCT07483801 | Mar 2026 → Apr 2027 expected | cardiovascular disorder | Cambridge University Hospitals NHS Foundation Trust | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07242534 | Jan 2026 → Feb 2027 expected | infertility disorder, obesity disorder | Fundacion Dexeus | Recruiting | No outcome recorded |
| Phase 4 | NCT07213466 | Jan 2026 → Feb 2028 expected | bipolar I disorder, bipolar II disorder, obesity disorder, schizoaffective disorder | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 4 | NCT07275697 | Dec 2025 → Dec 2028 expected | atrial fibrillation, obesity disorder | Emma Svennberg | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07251556 | Dec 2025 → Jan 2027 expected | psoriatic arthritis | Chinese University of Hong Kong | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07017270 | Nov 2025 → Jul 2027 expected | end stage renal failure, type 2 diabetes mellitus | Unity Health Toronto | Recruiting | No outcome recorded |
| Phase 4 | NCT07178145 | Nov 2025 → Sep 2029 expected | symptomatic heart failure | University of Virginia | Recruiting | No outcome recorded |
| Phase 4 | NCT06801015 | Oct 2025 → Jan 2028 expected | obesity disorder | Mayo Clinic | Active not recruiting | No outcome recorded |
| Phase 4 | NCT07073053 | Oct 2025 → Jul 2028 expected | coronary artery disorder, type 2 diabetes mellitus | Taipei Veterans General Hospital, Taiwan | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07165158 | Sep 2025 → Dec 2026 expected | osteoporosis, type 2 diabetes mellitus | The First Affiliated Hospital of Xiamen University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07136714 | Sep 2025 → Sep 2027 expected | major depressive disorder | Nordsjaellands Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT07314684 | Sep 2025 → Mar 2027 expected | type 2 diabetes mellitus | Federico II University | Recruiting | No outcome recorded |
| Phase 4 | NCT07513168 | Aug 2025 → Aug 2026 overdue | obesity disorder | Asian Institute Of Medical Sciences | Recruiting | No outcome recorded |
| Phase 4 | NCT07254572 | Jul 2025 → Aug 2029 expected | coronary atherosclerosis, prediabetes syndrome | National Institute of Cardiology, Warsaw, Poland | Recruiting | No outcome recorded |
| Phase 4 | NCT06908694 | Jul 2025 → Oct 2027 expected | prostate cancer | Hamilton Health Sciences Corporation | Active not recruiting | No outcome recorded |
| Phase 4 | NCT07239570 | Jun 2025 → Jun 2028 expected | chronic kidney disease | Peter Rossing | Recruiting | No outcome recorded |
| Phase 4 | NCT06852391 | Jun 2025 → Dec 2027 expected | obesity disorder | McMaster University | Recruiting | No outcome recorded |
| Phase 4 | NCT06851962 | May 2025 → Jun 2026 | type 2 diabetes mellitus | Fundación para la Investigación del Hospital Clínico de Valencia | Completed | No outcome recorded |
| Phase 4 | NCT07057310 | May 2025 → Dec 2026 expected | obesity disorder | Mayo Clinic | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT06706284 | Apr 2025 → Sep 2028 expected | spinal cord injury, type 2 diabetes mellitus | Marzieh Salehi | Recruiting | No outcome recorded |
| Phase 4 | NCT06854614 | Mar 2025 → Apr 2027 expected | obesity disorder | The Cleveland Clinic | Active not recruiting | No outcome recorded |
| Phase 4 | NCT06814938 | Feb 2025 → Dec 2027 expected | obesity disorder | Mayo Clinic | Active not recruiting | No outcome recorded |
| Phase 4 | NCT06754163 | Jan 2025 → Jul 2027 expected | obesity disorder, psychiatric disorder | St Andrew's Healthcare | Active not recruiting | No outcome recorded |
| Phase 4 | NCT06792422 | Jan 2025 → Aug 2028 expected | open-angle glaucoma | Glostrup University Hospital, Copenhagen | Recruiting | No outcome recorded |
| Phase 4 | NCT06396416 | Sep 2024 → Sep 2026 overdue | chronic kidney disease, obesity disorder | Western University, Canada | Recruiting | No outcome recorded |
| Phase 4 | NCT06571383 | Sep 2024 → Nov 2028 expected | obesity disorder | Novo Nordisk A/S | Active not recruiting | No outcome recorded |
| Phase 4 | NCT06557811 | Sep 2024 overdue | acute myocardial infarction | University of Sao Paulo General Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06468748 | Aug 2024 → Mar 2025 | obesity disorder | United States Army Research Institute of Environmental Medicine | Withdrawn | No outcome recorded Stop: Business |
| Phase 4 | NCT06461377 | Jun 2024 → Dec 2026 expected | diabetic autonomic neuropathy, type 2 diabetes mellitus | The First Affiliated Hospital with Nanjing Medical University | Recruiting | No outcome recorded |
| Phase 4 | NCT06003153 | Mar 2024 → May 2027 expected | type 2 diabetes mellitus | Massachusetts General Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT06243536 | Feb → Dec 2024 | eating disorder, obesity disorder, type 2 diabetes mellitus | University Hospital Sestre Milosrdnice | Unknown | No outcome recorded |
| Phase 4 | NCT06959784 | Jan 2024 → Dec 2026 expected | cerebrovascular disorder, diabetes mellitus | China-Japan Friendship Hospital | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT06042153 | Dec 2023 → Sep 2027 expected | end stage renal failure, type 2 diabetes mellitus | University of Texas Southwestern Medical Center | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05702905 | May 2023 → Dec 2024 | polycystic ovary syndrome | Peking University First Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT06475586 | May 2023 → Mar 2024 | psoriasis, type 2 diabetes mellitus | University of Banja Luka | Completed | No outcome recorded |
| Phase 4 | NCT05209165 | May 2023 → May 2027 | atrial fibrillation, obesity disorder | San Francisco Veterans Affairs Medical Center | Suspended | No outcome recorded |
| Phase 4 | NCT05870462 | Apr 2023 → Dec 2024 | atherosclerosis, diabetes mellitus, noninsulin-dependent, 2, obesity disorder | Canadian Medical and Surgical Knowledge Translation Research Group | Unknown | No outcome recorded |
| Phase 4 | NCT05786521 | Apr 2023 → May 2024 | prediabetes syndrome, type 2 diabetes mellitus | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 4 | NCT07272343 | Feb 2023 → Jun 2026 overdue | type 2 diabetes mellitus | Second Affiliated Hospital of Nanchang University | Recruiting | No outcome recorded |
| Phase 4 | NCT05579249 | Jan 2023 → Nov 2024 | obesity disorder | Novo Nordisk A/S | Completed | Met primary |
| Phase 4 | NCT05597202 | Jan 2023 → Mar 2024 | type 2 diabetes mellitus | Academic Medical Center - University of Amsterdam | Unknown | No outcome recorded |
| Phase 4 | NCT05195944 | Oct 2022 → Dec 2026 expected | NAFLD1, diabetes mellitus, metabolic dysfunction-associated steatohepatitis | University Health Network, Toronto | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT06027567 | Sep 2022 → Jan 2025 | obesity disorder, pseudotumor cerebri | Rigmor Højland Jensen | Completed | No outcome recorded |
| Phase 4 | NCT05442450 | Jul 2022 → Jun 2023 | obesity disorder | Asian Institute of Gastroenterology, India | Unknown | No outcome recorded |
| Phase 4 | NCT05533632 | Apr 2022 → Jan 2024 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 4 | NCT04854083 | Feb 2022 → Aug 2025 | type 2 diabetes mellitus | Kirsi Pietiläinen | Unknown | No outcome recorded |
| Phase 4 | NCT04873050 | Jan 2022 → Jan 2026 overdue | prediabetes syndrome, puerperal disorder | Woman's | Recruiting | No outcome recorded |
| Phase 4 | NCT04979130 | Jan 2022 → Oct 2024 | type 2 diabetes mellitus | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 4 | NCT05119179 | Nov 2021 → Oct 2026 expected | prediabetes syndrome | The University of Texas Health Science Center, Houston | Recruiting | No outcome recorded |
| Phase 4 | NCT05606471 | Sep 2021 → Jul 2023 | type 2 diabetes mellitus | University of Nottingham | Unknown | No outcome recorded |
| Phase 4 | NCT05035082 | Sep 2021 → Jun 2025 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 4 | NCT04639414 | Mar 2021 → Jan 2025 | NAFLD1, metabolic dysfunction-associated steatohepatitis, type 2 diabetes mellitus | German Diabetes Center | Completed | No outcome recorded |
| Phase 4 | NCT04538352 | Jan 2021 → Mar 2023 | type 2 diabetes mellitus | The Cleveland Clinic | Completed | No outcome recorded |
| Phase 4 | NCT04189848 | Dec 2019 → Jan 2020 | obesity disorder, type 2 diabetes mellitus | Novo Nordisk A/S | Completed | Met primary |
| Phase 4 | NCT04263415 | Nov 2019 → May 2020 | oral sensibility, disturbance of, polycystic ovary syndrome | University Medical Centre Ljubljana | Completed | No outcome recorded |
| Phase 4 | NCT03292315 | Oct 2018 → Mar 2020 | obesity disorder, prediabetes syndrome, spinal cord injury | James J. Peters Veterans Affairs Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT03596450 | Jul 2018 → Jun 2022 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | Met primary |
| Phase not applicable31 trials · 1 met primary · 1 missed | ||||||
| — | NCT07586150 | Oct 2028 → Jul 2030 expected | bipolar disorder, major depressive disorder, schizophrenia | Ludwig-Maximilians - University of Munich | Not yet recruiting | No outcome recorded |
| — | NCT07677995 | Sep → Dec 2026 expected | cardiovascular disorder, type 2 diabetes mellitus | University of Ulster | Enrolling by invitation | No outcome recorded |
| — | NCT07621640 | Jun 2026 → Feb 2028 expected | abdominal obesity-metabolic syndrome, obesity disorder | Hallym University | Not yet recruiting | No outcome recorded |
| — | NCT06546384 | May → Dec 2026 expected | alcohol-related disorders, fatty liver disease, obesity disorder | Insel Gruppe AG, University Hospital Bern | Not yet recruiting | No outcome recorded |
| — | NCT07633639 | May 2026 → May 2028 expected | obesity disorder | China-Japan Friendship Hospital | Recruiting | No outcome recorded |
| — | NCT07599046 | Apr 2026 → Jan 2027 expected | type 2 diabetes mellitus | Eighth Affiliated Hospital, Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| — | NCT07391267 | Feb 2026 → Dec 2028 expected | chronic kidney disease, metabolic dysfunction-associated steatotic liver disease | Institute of Liver and Biliary Sciences, India | Not yet recruiting | No outcome recorded |
| — | NCT07319975 | Dec 2025 → Oct 2026 expected | obesity disorder | Istanbul Galata University | Not yet recruiting | No outcome recorded |
| — | NCT07091500 | Aug 2025 → Aug 2028 expected | obesity disorder, skeletal muscle disorder | Washington University School of Medicine | Recruiting | No outcome recorded |
| — | NCT06924697 | Jun 2025 → Jan 2026 overdue | nicotine dependence, type 2 diabetes mellitus | Shanghai East Hospital | Enrolling by invitation | No outcome recorded |
| — | NCT06989203 | Jun 2025 → Dec 2026 expected | obesity disorder | Chinese Academy of Sciences | Recruiting | No outcome recorded |
| — | NCT07293325 | Jun 2025 → Apr 2027 expected | obesity disorder | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| — | NCT06715514 | Feb 2025 → Dec 2026 expected | type 2 diabetes mellitus | Lia Bally | Recruiting | No outcome recorded |
| — | NCT06608433 | Jan → Oct 2025 | adrenocortical insufficiency | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| — | NCT06555146 | Aug 2024 → Mar 2025 overdue | chronic kidney disease, type 2 diabetes mellitus | Bispebjerg Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06363487 | Jun → Dec 2024 | — | University of Oxford | Completed | No outcome recorded |
| — | NCT06318442 | May 2024 → Jun 2027 expected | hyperglycemia | Imperial College London | Recruiting | No outcome recorded |
| — | NCT07368855 | May 2024 → Jul 2025 | depressive disorder, obesity disorder | University of California, San Diego | Completed | No outcome recorded |
| — | NCT06390501 | Apr 2024 → Aug 2025 | obesity disorder | Shenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences | Completed | No outcome recorded |
| — | NCT06629688 | Nov 2023 → Apr 2024 | iron metabolism disease, type 2 diabetes mellitus | University Hospital Dubrava | Completed | No outcome recorded |
| — | NCT06060392 | Oct 2023 → Sep 2025 overdue | diabetes mellitus | Medanta, The Medicity, India | Recruiting | No outcome recorded |
| — | NCT05390307 | Apr 2023 → Jan 2024 | type 1 diabetes mellitus | Dasman Diabetes Institute | Completed | No outcome recorded |
| — | NCT05779644 | Feb 2023 → Feb 2025 | abdominal obesity-metabolic syndrome, metabolic dysfunction-associated steatotic liver disease, type 2 diabetes mellitus | RenJi Hospital | Unknown | No outcome recorded |
| — | NCT05501483 | Feb 2023 → Sep 2026 overdue | type 2 diabetes mellitus | Karolinska Institutet | Recruiting | No outcome recorded |
| — | NCT05340868 | Sep 2022 → Dec 2025 overdue | obesity disorder, prediabetes syndrome | Medical University of Bialystok | Recruiting | No outcome recorded |
| — | NCT04174755 | Jun 2022 → Jan 2027 expected | HIV infectious disease, obesity disorder | University College Dublin | Recruiting | No outcome recorded |
| — | NCT05333003 | May 2022 → Aug 2026 overdue | schizophrenia | Centre for Addiction and Mental Health | Active not recruiting | No outcome recorded |
| — | NCT07539584 | Mar 2022 → Apr 2024 | metabolic dysfunction-associated steatotic liver disease, type 2 diabetes mellitus | Moscow Regional Research and Clinical Institute (MONIKI) | Completed | No outcome recorded |
| — | NCT05078255 | Jan 2022 → Jan 2025 | obesity disorder, type 2 diabetes mellitus | Asger Lund, MD | Completed | Missed primary |
| — | NCT04383197 | Dec 2019 → Aug 2021 | type 2 diabetes mellitus | University of Copenhagen | Unknown | Met primary |
| — | NCT03498001 | Apr 2018 → Jun 2023 | type 2 diabetes mellitus | Centre Hospitalier Universitaire Dijon | Completed | No outcome recorded |
| Comparator or background therapy167 trials | ||||||
| Phase 0 | NCT07092605 Comparator | Nov 2024 → Nov 2025 overdue | — | AgelessRx | Enrolling by invitation | No outcome recorded |
| Phase 1 | NCT07767175 Comparator | Aug 2026 → Sep 2027 expected | obesity disorder | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 1 | NCT07430059 Comparator | Jul → Dec 2026 expected | obesity disorder | Vivani Medical, Inc | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07673900 Comparator | Jun 2026 → Feb 2027 expected | obesity disorder | Terrestrial Bio, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT07539415 Comparator | May → Oct 2026 expected | obesity disorder, type 2 diabetes mellitus | Daewoong Pharmaceutical Co. LTD. | Recruiting | No outcome recorded |
| Show all 167 trials opens the full record — a long page | ||||||
News releases announcing trial results or a regulatory action · 159
| Date | Issuer | Release |
|---|---|---|
| 2026-10-01 | Novo Nordisk A/S | Results Novo’s Wegovy® (semaglutide) reduced liver fat to normal levels in 9 out of 10 adults with obesity and excess liver fat – EASD2026 novonordisk.com ↗
Novo Nordisk today presented post hoc analysis of data from a STEP UP trial sub-population with 55 participants, showing that Wegovy® (pooled semaglutide 7.2 and 2.4 mg) reduced liver fat in adults with obesity without diabetes. |
| 2026-10-01 | Regeneron Pharmaceuticals | Results Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss regeneron.com ↗
A pre-specified subgroup analysis found that patients meeting the low lean mass definition for sarcopenia had greater loss of lean mass with semaglutide, and more preservation with trevogrumab |
| 2026-09-30 | Novo Nordisk A/S | Results Novo’s investigational obesity and diabetes drug CagriSema reduces ‘food noise’ and shows benefits in organ and bone health – EASD 2026 novonordisk.com ↗
Additionally, CagriSema substantially improved eating behaviour, reduced ‘food noise’, cravings, hunger, appetite, and food-related thoughts and improved craving control after both 22 and 52 weeks of treatment. |
| 2026-09-30 | Novo Nordisk A/S | Results People switching from weight-loss injections to Novo's Wegovy® pill lost 4.1% body weight on average after three months, according to real-world data presented at EASD2026 novonordisk.com ↗
People with overweight or obesity who switched from injectable GLP-1 based therapies for weight management to oral semaglutide (Wegovy® pill) lost an average of 4.0 kg (8.8 lb) in three months (p<0.001)¹ |
| 2026-09-30 | Novonordisk Us | Results People switching from weight-loss injections to Novo's Wegovy® pill lost 4.1% body weight on average after three months, according to real-world data presented at EASD2026 novonordisk-us.com ↗
In the study, adults with overweight or obesity who switched from an injectable GLP-1 based medicine for weight management - either tirzepatide or semaglutide - to once-daily oral semaglutide (Wegovy® pill) and stayed on treatment for 3 months lost an average of 4.1% or 8.8 lbs based on an average starting weight of 221.6 lbs (p <0.001). |
| 2026-09-29 | Novo Nordisk A/S | Results Novo’s Ozempic® (semaglutide) 2 mg associated with lower risk of major adverse cardiovascular events (death, heart attack, and stroke) in adults with type 2 diabetes compared to switching to Mounjaro® (tirzepatide), in real-world analysis novonordisk.com ↗
Novo’s Ozempic® (semaglutide) 2 mg associated with lower risk of major adverse cardiovascular events (death, heart attack, and stroke) in adults with type 2 diabetes compared to switching to Mounjaro® (tirzepatide), in real-world analysis |
| 2026-09-29 | Novonordisk Us | Results Novo's Ozempic® (semaglutide) 2 mg associated with lower risk of major adverse cardiovascular events (death, heart attack, and stroke) in adults with type 2 diabetes compared to switching to Mounjaro® (tirzepatide), in real-world analysis at EASD novonordisk-us.com ↗
These findings were presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026 in Milan, Italy. |
| 2026-09-29 | Eli Lilly and Company | Results Lilly's Zepbound (tirzepatide 10 mg and 15 mg) was associated with more weight loss than Wegovy HD (semaglutide injection 7.2 mg) in a new indirect treatment comparison lilly.com ↗
In this new analysis, Zepbound 15 mg showed 4.5% greater weight loss than Wegovy HD in adults with obesity |
| 2026-09-29 | Eli Lilly and Company | Results Lilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indirect treatment comparison lilly.com ↗
In an indirect treatment comparison using data from ACHIEVE-3 and PIONEER PLUS, Foundayo 17.2 mg showed significantly greater weight loss and A1C reduction compared to oral semaglutide 25 mg at 52 weeks. |
| 2026-09-21 | Novo Nordisk A/S | Results Novo's CagriSema delivers superior weight loss versus tirzepatide in REIMAGINE 5 trial novonordisk.com ↗
In REIMAGINE 5, CagriSema 1.0 mg/1.0 mg was superior to tirzepatide 5 mg for weight loss, achieving an estimated average weight loss of 12.4%, compared with 9.1%, respectively. |
| 2026-09-18 | Sandoz | Regulatory Sandoz receives regulatory approval for generic semaglutide in Canada, paving way to expand patient access to key GLP-1 medicine sandoz.com ↗
Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in affordable medicines, today announces that Health Canada has granted marketing authorisation for Sandoz® Semaglutide (semaglutide), a GLP-1 receptor agonist injection and a generic version of Ozempic®*. |
| 2026-09-07 | Novo Nordisk A/S | Results Novo Nordisk STEP Young phase 3 data: 40.4% of children living with obesity achieved a BMI below the obesity threshold with semaglutide and lifestyle modification novonordisk.com ↗
The trial met its primary endpoint demonstrating superior BMI reduction at week 68 in the group taking semaglutide compared with the placebo group. |
| 2026-08-20 | Celon Pharma SA | Results Raport bieżący 17/2026 – Pozytywne wyniki badania równoważności semaglutydu Celon (Reduzek) celonpharma.com ↗
Badanie wykazało biorównoważność Semaglutydu Celon 0,5 mg (Reduzek) zarówno względem Wegovy(R), jak i Ozempic(R). |
| 2026-08-05 | Rezera (formerly NodThera Limited) | Results NodThera’s Oral NLRP3 Inhibitor NT-0796 Enhances and Sustains Weight Loss in Combination with GLP-1 rezera.com ↗
These data, published in the research journal Obesity, show that combined dosing of NodThera’s NT-0796 with semaglutide (Wegovy®) drove greater weight loss than either monotherapy in an animal model of obesity. |
| 2026-06-30 | Apotex Inc. | Regulatory Apotex first to receive Health Canada approval for SEVMIA™, a generic semaglutide for chronic weight management apotex.com ↗
This approval follows Health Canada's recent approval of Apo Semaglutide Injection ™, and reflects Apotex's continued focus on bringing high-quality, affordable medicines to Canadians. |
| 2026-06-25 | Vivani Medical, Inc | Regulatory Vivani Medical Receives Regulatory Approval for the Initiation of SLIM-1, a Phase 1 Clinical Trial of NPM-139 Semaglutide Implant in Obesity and Chronic Weight Management vivani.com ↗
HREC approval to initiate SLIM-1 in Australia marks an important moment for our Company, clearing the way for near-term, mid-2026, initiation. |
| 2026-06-19 | Sumitomo Pharma America, Inc. | Regulatory Wegovy Subcutaneous Injection, Co-Promoted with Novo Nordisk Pharma, Approved in Japan for Metabolic Dysfunction-Associated Steatohepatitis (MASH) sumitomo-pharma.com ↗
This approval covers an additional indication for metabolic dysfunction-associated steatohepatitis (“MASH”) without cirrhosis in patients with moderate to advanced fibrosis. |
| 2026-06-17 | Lexaria Bioscience Corp. | Results GLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to Expand lexariabioscience.com ↗
The following table summarizes the dramatic improvements in GI AEs that Lexaria has realized when testing three (semaglutide, tirzepatide, and liraglutide) of the major GLP-1 drugs on the market today with its DehydraTECH™ technology in an oral format: |
| 2026-06-08 | Inventage Lab., Inc. | Results 인벤티지랩, 세마글루타이드·티르제파타이드 모두 잡는다…미국비만학회 (ADA) 2026서 LAI 플랫폼 기술 경쟁력 확인 inventagelab.com ↗
세마글루타이드(Semaglutide) 기반 월 1회 장기지속형 주사제(Long-Acting Injectable, LAI)인 IVL3021은 고지방식이(DIO) 비만 랫드 모델 평가에서 용량 의존적인 체중 감소 효과를 명확히 입증했다. |
| 2026-06-08 | Innovent Biologics (Suzhou) Co. Ltd. | Results 2026ADA | Innovent Biologics Presents Results of DREAMS-3: the First Globally Approved GCG/GLP-1 Dual Receptor Agonist versus Semaglutide in a Head-to-Head Phase 3 Randomized Controlled Trial innoventbio.com ↗
Mazdutide demonstrated superior glycemic control and weight reduction versus semaglutide |
| 2026-06-07 | Novo Nordisk A/S | Results Novo Nordisk’s CagriSema 2.4 mg / 2.4 mg demonstrated significant reduction in HbA1c and weight across multiple studies in the REIMAGINE program presented at ADA 2026 novonordisk.com ↗
CagriSema, a once-weekly investigational treatment that combines a novel amylin analog with a GLP-1 receptor agonist (RA), achieved significant reductions in HbA1c and bodyweight versus comparators across three phase 3 trials in adults with type 2 diabetes (T2D)1-3 |
| 2026-06-06 | Novo Nordisk A/S | Results Novo Nordisk to present new data on Wegovy® across a wide range of cardiometabolic conditions at the American Diabetes Association's 2026 Scientific Sessions novonordisk.com ↗
Two of the post hoc analyses demonstrated semaglutide use was associated with a reduction of asthma-related adverse outcomes and improvements in systolic blood pressure for those with uncontrolled hypertension and overweight or obesity, respectively2-3 |
| 2026-06-06 | Novo Nordisk A/S | Results People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more likely to achieve greater than 5% weight loss than those who were switched to tirzepatide, in real-world data novonordisk.com ↗
This retrospective cohort analysis, drawn from a large US claims database (January 2018 - September 2025), supports escalating to semaglutide 2 mg as a clinically appropriate and effective treatment strategy. |
| 2026-06-06 | Novonordisk Us | Results Novo Nordisk to present new data on Wegovy® across a wide range of cardiometabolic conditions at the American Diabetes Association's 2026 Scientific Sessions novonordisk-us.com ↗
Two of the post hoc analyses demonstrated semaglutide use was associated with a reduction of asthma-related adverse outcomes and improvements in systolic blood pressure for those with uncontrolled hypertension and overweight or obesity, respectively2-3 |
| 2026-05-22 | Novo Nordisk A/S | Regulatory Novo Nordisk A/S: CHMP recommends EU approval of Wegovy® 7.2 mg in a single-dose pen, providing up to 20.7% mean weight loss (1) novonordisk.com ↗
Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing authorisation of Wegovy® 7.2 mg (once-weekly injectable semaglutide 7.2 mg) in a single-dose pen for people living with obesity. |
| 2026-05-22 | Novo Nordisk A/S | Regulatory Novo Nordisk A/S: Wegovy® pill (oral semaglutide) recommended by CHMP for approval in the EU as the first oral GLP-1 representing the most efficacious oral obesity treatment in its class novonordisk.com ↗
CHMP recommends Wegovy® pill for approval to reduce excess body weight and maintain long-term weight reduction. |
| 2026-05-12 | Eli Lilly and Company | Results Lilly's Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials lilly.com ↗
In ATTAIN-MAINTAIN, participants who transitioned from a maximum tolerated dose (MTD) of Wegovy (semaglutide) to Foundayo maintained all but 0.9 kg of their previously achieved weight loss on average after one year |
| 2026-05-01 | Apotex Inc. | Regulatory Apotex becomes the first Canadian-based global pharmaceutical company to receive Health Canada approval for a generic equivalent of Ozempic® apotex.com ↗
Toronto, ON – May 1, 2026 — Apotex ("Apotex" or the "Company"), the largest Canadian-based global health company, today announced that Health Canada has approved Apo-Semaglutide Injection™, a generic equivalent of Ozempic® (semaglutide injection). |
| 2026-04-02 | Novo Nordisk A/S | Results Wegovy® pill demonstrated greater weight loss than orforglipron and lower odds of stopping medication due to side effects in a new indirect comparison to be presented at Obesity Medicine Association 2026 novonordisk.com ↗
Oral semaglutide 25 mg demonstrated significantly greater mean weight loss than orforglipron 36 mg in a population-adjusted indirect treatment comparison (ITC) using data from the OASIS 4 and ATTAIN-1 clinical trials1 |
| 2026-04-02 | Novonordisk Us | Results Wegovy® pill demonstrated greater weight loss than orforglipron and lower odds of stopping medication due to side effects in a new indirect comparison to be presented at Obesity Medicine Association 2026 novonordisk-us.com ↗
Oral semaglutide 25 mg demonstrated significantly greater mean weight loss than orforglipron 36 mg in a population-adjusted indirect treatment comparison (ITC) using data from the OASIS 4 and ATTAIN-1 clinical trials1 |
| 2026-03-19 | Novo Nordisk A/S | Regulatory Novo Nordisk A/S: Wegovy® HD (semaglutide 7.2 mg) approved in the US, providing 20.7% mean weight loss novonordisk.com ↗
Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Wegovy® HD (once-weekly injectable semaglutide 7.2 mg) to reduce excess body weight and maintain weight reduction long-term. |
| 2026-03-19 | Nanexa AB | Results Nanexa Demonstrates Feasibility of Quarterly Semaglutide Dosing with PharmaShell® nanexa.com ↗
These new data, in combination with human modelling, indicate that semaglutide can potentially be administered once every three months (quarterly) while maintaining a controlled and therapeutically relevant plasma concentration. |
| 2026-02-26 | Eli Lilly and Company | Results Lilly's oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet lilly.com ↗
In ACHIEVE-3, orforglipron outperformed oral semaglutide across the primary and all key secondary endpoints, delivering significantly greater improvements in A1C and weight. |
| 2026-02-23 | Novo Nordisk A/S | Results Novo Nordisk A/S: CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity, the primary endpoint was not achieved novonordisk.com ↗
CagriSema achieved 23% weight loss after 84 weeks of treatment |
| 2026-02-02 | Novo Nordisk A/S | Results Novo Nordisk A/S: CagriSema demonstrated superior HbA1c reduction of 1.91%-points and weight loss of 14.2% in adults with type 2 diabetes in the REIMAGINE 2 trial novonordisk.com ↗
CagriSema demonstrated both superior HbA1c reduction and weight loss at week 68 versus semaglutide, across all tested doses in the trial. |
| 2026-02-02 | Skye Bioscience, Inc. | Results Skye Reports Positive CBeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With Semaglutide skyebioscience.com ↗ |
| 2026-01-29 | Skye Bioscience, Inc. | Results Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference skyebioscience.com ↗
Nimacimab enhanced weight loss induced by semaglutide. |
| 2026-01-27 | Nanexa AB | Results Nanexa Announces Breakthrough Preclinical Data Demonstrating Exceptional Pharmacokinetic Profile for Monthly Semaglutide Formulation nanexa.com ↗
Nanexa AB today announces exceptional preclinical results for its long-acting semaglutide formulation developed using the company’s proprietary PharmaShell® drug delivery platform. |
| 2025-12-30 | Lexaria Bioscience Corp. | Results Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4 lexariabioscience.com ↗
Plasma semaglutide concentrations were not quantifiable in the DHT-semaglutide and DHT-CBD with DHT-semaglutide arms. |
| 2025-12-23 | Lexaria Bioscience Corp. | Results Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4 lexariabioscience.com ↗
DehydraTECH-semaglutide reduced overall side effects by 48% as compared to Rybelsus ® |
| 2025-12-22 | Novo Nordisk A/S | Regulatory Novo Nordisk A/S: Wegovy® pill approved in the US as first oral GLP-1 for weight management novonordisk.com ↗
Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the Wegovy® pill (once-daily oral semaglutide 25 mg) to reduce excess body weight and maintain weight reduction long term and to reduce the risk of major adverse cardiovascular events*. |
| 2025-12-18 | Novo Nordisk A/S | Regulatory Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues for weight management novonordisk.com ↗ |
| 2025-11-26 | Novo Nordisk A/S | Regulatory Novo Nordisk files for FDA approval of a higher dose of Wegovy® injection 7.2 mg novonordisk.com ↗
Today, Novo Nordisk announced the submission of a sNDA to the U.S. Food and Drug Administration (FDA) for a higher dose of semaglutide injection 7.2 mg, to be used along with a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity. |
| 2025-11-24 | Novo Nordisk A/S | Results Novo Nordisk A/S: Evoke phase 3 trials did not demonstrate a statistically significant reduction in Alzheimer's disease progression novonordisk.com ↗
The evoke and evoke+ trials did not confirm superiority of semaglutide versus placebo in the reduction of progression of Alzheimer’s disease, as measured by the change in Clinical Dementia Rating – Sum of Boxes (CDR-SB) score compared to baseline. |
| 2025-11-10 | Novo Nordisk A/S | Results Novo Nordisk’s Wegovy® (semaglutide 2.4 mg) was associated with liver health-related benefits not solely based on weight loss in adult patients with MASH with liver scarring, according to a new post hoc analysis novonordisk.com ↗
Results from a post hoc analysis of the ESSENCE phase 3 trial showed semaglutide 2.4 mg was associated with reduction in liver injury (steatohepatitis) in adults with MASH even at low levels of weight loss. |
| 2025-11-10 | Camurus AB | Results Camurus reports positive topline results for CAM2056, semaglutide monthly depot camurus.com ↗
The study showed that CAM2056, given as two biweekly initiation doses followed by two monthly doses, was well tolerated, up to the highest initiation dose, and significantly reduced body weight, hemoglobin A1c (A1c), and fasting glucose in a dose-dependent manner. |
| 2025-11-06 | Novo Nordisk A/S | Results Novo Nordisk's CagriSema associated with significant reduction in blood pressure and showed anti-inflammatory effects while reducing the proportion of patients at risk of developing heart disease over time in new analyses at ObesityWeek® novonordisk.com ↗
With CagriSema treatment, systolic blood pressure was reduced by -10.9 mmHg over 68 weeks (versus -8.8 mmHg with semaglutide 2.4 mg and -2.1 mmHg with placebo).* |
| 2025-11-05 | Novo Nordisk A/S | Results Novo Nordisk presents four new analyses on oral semaglutide 25 mg (Wegovy® in a pill*) at ObesityWeek® 2025, including demonstrated reductions in cardiovascular risk factors novonordisk.com ↗
Results showed that in the overall trial population, a higher percentage of participants with pre-diabetes at baseline achieved normal blood glucose (sugar) at week 64 in the semaglutide group versus placebo (71.1% versus 33.3%). |
| 2025-11-05 | Skye Bioscience, Inc. | Results Skye Bioscience Late-Breaking Oral Abstract at ObesityWeek 2025 to Highlight Improvement in Rebound Weight Gain skyebioscience.com ↗
New data from an analysis of participants 12 weeks post-treatment demonstrated that nimacimab 200 mg (subcutaneous, weekly) plus semaglutide blunted rebound weight gain compared to semaglutide alone (18.1% versus 49.8% weight regain over 12 weeks). |
| 2025-10-28 | Innovent Biologics (Suzhou) Co. Ltd. | Results Innovent’s Mazdutide Shows Superiority in Glycemic Control with Weight Loss over Semaglutide in a Head-to-head Phase 3 Clinical Trial DREAMS-3 innoventbio.com ↗
The proportion of participants achieving HbA1c < 7.0% and a ≥10% reduction in body weight from baseline was 48.0% in the mazdutide group and 21.0% in the semaglutide group |
| 2025-10-06 | Skye Bioscience, Inc. | Results Skye Bioscience Reports Topline CBeyond™ Phase 2a Data from Nimacimab Monotherapy and Combination Clinical Trial skyebioscience.com ↗
In the combination cohort, nimacimab 200 mg (subcutaneous, weekly) plus semaglutide demonstrated a clinically meaningful magnitude of weight loss compared to semaglutide alone (-13.2% vs -10.25%, p=0.0372, mITT), with no plateau being observed through Week 26. |
| 2025-09-19 | Lexaria Bioscience Corp. | Results Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain lexariabioscience.com ↗
In fact, the 5mg DehydraTECH-FTS composition achieved higher brain semaglutide fluorescent signal intensity than the 15mg Rybelsus® equivalent composition. |
| 2025-09-17 | Regeneron Pharmaceuticals | Results Results from Phase 2 COURAGE Trial Demonstrating Potential to Improve Quality of GLP-1 receptor agonist-induced Weight Loss by Preserving Lean Mass, Presented at EASD regeneron.com ↗
Complete 26-week results further demonstrate that combining semaglutide with trevogrumab (anti-GDF8/anti-myostatin) helped prevent about half of semaglutide-induced loss of lean mass, while increasing fat mass loss |
| 2025-09-17 | Eli Lilly and Company | Results Lilly's oral GLP-1, orforglipron, superior to oral semaglutide in head-to-head trial lilly.com ↗
At 52 weeks, orforglipron met the primary and all key secondary endpoints across each dose comparison vs. oral semaglutide, delivering greater improvements in A1C and weight. |
| 2025-09-05 | Orexo AB | Results Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication orexo.com ↗
Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announced positive pharmacokinetic in-vivo data for a powder-based intranasal semaglutide formulation developed with the AmorphOX technology. |
| 2025-08-15 | Novo Nordisk A/S | Regulatory Novo Nordisk A/S: Wegovy® approved in the US for the treatment of MASH novonordisk.com ↗ |
| 2025-08-05 | Vivani Medical, Inc | Results Vivani Medical Announces Rapid Advancement of NPM-139, a Novel Semaglutide Implant, Following Positive Weight Loss Data from an Ongoing Preclinical Study of NPM-139 and Promising Results from the LIBERATE-1 Phase 1 Clinical Study of NPM-115 vivani.com ↗
New NPM-139 (semaglutide implant) preclinical feasibility data showed approximately 20% weight loss maintained longer than 6 months with a single implant, continuing to support the potential for annual dosing |
| 2025-08-01 | Regeneron Pharmaceuticals | Results Regeneron Reports Second Quarter 2025 Financial and Operating Results regeneron.com ↗
The Company announced interim 26-week results from the ongoing Phase 2 COURAGE trial investigating combinations of semaglutide and trevogrumab (myostatin antibody) with or without garetosmab (Activin A antibody) for the treatment of obesity. |
| 2025-07-28 | Lexaria Bioscience Corp. | Results Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study lexariabioscience.com ↗
DehydraTECH-semaglutide reduces overall side effects by 36.5% as compared to Rybelsus® |
| 2025-06-17 | Eccogene | Results Eccogene to Report Preclinical Data with ECC4703, Showcasing Impact on Lean Muscle Sparing and Fat Loss in Combination with Semaglutide and Tirzepatide eccogene.com ↗
The combination therapy of ECC4703 and semaglutide or tirzepatide resulted in significantly greater weight loss compared to semaglutide or tirzepatide alone. |
| 2025-06-02 | Regeneron Pharmaceuticals | Results Interim Results from Ongoing Phase 2 COURAGE Trial Confirm Potential to Improve the Quality of Semaglutide (GLP-1 receptor agonist)-induced Weight Loss by Preserving Lean Mass regeneron.com ↗
The trial demonstrated that approximately 35% of semaglutide-induced weight loss was due to loss of lean mass, and further demonstrated that combining semaglutide with trevogrumab with or without garetosmab helped preserve lean mass while increasing loss of fat mass. |
| 2025-05-29 | Gan and Lee Pharmaceuticals, USA | Results Multinational Diabetes Academic Conference 2025 Opens in Beijing, Gathering Global Experts to Explore New Trends in Prevention and Treatment ganlee.com ↗ |
| 2025-05-28 | Veru Inc. | Results Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone verupharma.com ↗
Enobosarm 3mg + semaglutide combination had the added benefit of fewer gastrointestinal side effects (Diarrhea, Nausea, and GERD) compared to semaglutide alone |
| 2025-05-11 | Eli Lilly and Company | Results Zepbound (tirzepatide) showed superior weight loss over Wegovy (semaglutide) in complete SURMOUNT-5 results published in The New England Journal of Medicine lilly.com ↗
For the primary endpoint, participants treated with Zepbound achieved an average weight reduction of 20.2% compared to 13.7% with Wegovy at 72 weeks using the treatment-regimen estimand,1 a 47% greater relative weight loss. |
| 2025-04-23 | Phenomix Sciences | Results Phenomix Sciences and Mayo Clinic to Present Landmark Research at DDW 2025, Advancing Precision Obesity Medicine phenomixsciences.com ↗
GLP-1 Receptor Agonist Semaglutide Induces Enteroendocrine Cell Alterations Persistent After Discontinuation |
| 2025-03-26 | Vivani Medical, Inc | Results Vivani Medical Announces Positive Preclinical Weight Loss Data for NPM-139 Semaglutide Implant, with Potential for Once-Yearly Dosing vivani.com ↗
Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced promising preclinical data for NPM-139, its subdermal semaglutide implant under development for chronic weight management in obese and overweight individuals. |
| 2025-03-10 | Novo Nordisk A/S | Results Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial novonordisk.com ↗
The trial achieved its primary endpoint by demonstrating a statistically significant and superior weight loss at week 68 with CagriSema versus placebo. |
| 2025-02-05 | RANI Therapeutics | Results Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via RaniPill® HC ranitherapeutics.com ↗
Oral semaglutide administered via the RaniPill® HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and weight loss to subcutaneous administration |
| 2025-01-17 | Novo Nordisk A/S | Results Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence novonordisk.com ↗
The trial achieved its primary endpoint by demonstrating a statistically significant and superior weight loss at week 72 with semaglutide 7.2 mg versus placebo. |
| 2025-01-10 | Tiziana Life Sciences LTD | Results Tiziana Announces Reduction of Side Effects Commonly Seen with Discontinuation of GLP-1 Agonists with Nasal Anti-CD3 tizianalifesciences.com ↗
This advancement offers a promising approach to overcoming the tolerability challenges and adverse effects commonly linked to prolonged GLP-1 drug use. |
| 2024-12-20 | Novo Nordisk A/S | Results Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial novonordisk.com ↗
In addition, 40.4% of patients who received CagriSema reached a weight loss of 25% or more after 68 weeks, compared to 6.0% with cagrilintide 2.4 mg, 16.2% with semaglutide 2.4 mg, and 0.9% with placebo. |
| 2024-12-18 | Ascletis Pharmaceuticals Co., Ltd. | Results Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model ascletis.com ↗ |
| 2024-12-12 | Novo Nordisk A/S | Regulatory Novo Nordisk A/S: European regulatory authority adopts positive opinion for an update of the Ozempic® label to reflect risk reduction of kidney disease-related events novonordisk.com ↗ |
| 2024-12-04 | Eli Lilly and Company | Results Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7% lilly.com ↗
On average, Zepbound led to a superior weight loss of 20.2% compared to 13.7% with Wegovy. |
| 2024-11-20 | iX Biopharma Ltd. | Results 19 NOVEMBER 2024, TUESDAY ixbiopharma.com ↗
Results showed that iXB 401 achieved a substantially higher area under the plasma concentration-time curve (AUC) over 8 hours compared to Rybelsus®. |
| 2024-11-20 | Lexaria Bioscience Corp. | Results ALL Study Groups using DehydraTECH Processing Outperform Rybelsus® in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study lexariabioscience.com ↗
The Study results were highlighted by the fact that all groups utilizing Lexaria’s proprietary DehydraTECH technology outperformed Rybelsus® in body weight-control, as well as experienced body weight-control improvement during the final 4-weeks of the Study. |
| 2024-11-06 | Novo Nordisk A/S | Results Novo Nordisk's sales increased by 23% in Danish kroner and by 24% at constant exchange rates to DKK 204.7 billion in the first nine months of 2024 novonordisk.com ↗
Further, within diabetes, Novo Nordisk announced that oral semaglutide statistically significantly reduced the risk of major adverse cardiovascular events in the SOUL cardiovascular outcomes trial. |
| 2024-11-01 | Novo Nordisk A/S | Results Novo Nordisk A/S: Semaglutide 2.4 mg demonstrates superior improvement in both liver fibrosis and MASH resolution in the ESSENCE trial novonordisk.com ↗
At week 72, 37.0% of people treated with semaglutide 2.4 mg achieved improvement in liver fibrosis with no worsening of steatohepatitis compared to 22.5% on placebo2. |
| 2024-10-30 | Tiziana Life Sciences LTD | Results Tiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study tizianalifesciences.com ↗
The data show that the combination of nasal anti-CD3 plus semaglutide improves liver homeostasis and reduces inflammation in models of diet-induced obesity (DIO), providing a potential novel approach to combat obesity-related inflammation, and liver inflammation and dysfunction. |
| 2024-10-24 | Lexaria Bioscience Corp. | Results Positive Partial 12-Week Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study lexariabioscience.com ↗
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces that it has received partial 12-week (final) blood sugar results from the recently completed animal study WEIGHT-A24-1 (the “Study”). |
| 2024-10-22 | Lexaria Bioscience Corp. | Results Positive Partial 12-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study lexariabioscience.com ↗
Actual weight decreases or slower rates of weight gain have since been achieved in the 12 weeks of dosing in all Study groups receiving DehydraTECH drug therapies. |
| 2024-10-21 | Novo Nordisk A/S | Results Novo Nordisk A/S: Oral semaglutide demonstrates a 14% reduction in risk of major adverse cardiovascular events in adults with type 2 diabetes in the SOUL trial novonordisk.com ↗
The trial achieved its primary objective by demonstrating a statistically significant and superior reduction in MACE of 14% for people treated with oral semaglutide compared to placebo1. |
| 2024-10-16 | Gan and Lee Pharmaceuticals, USA | Results Gan & Lee Pharmaceuticals’ Three Innovative Drugs: GZR18 Injection, GZR4 Injection, and GZR101 Injection Achieve Primary Endpoints in Phase 2 Clinical Studies ganlee.com ↗
After 24 weeks of treatment in patients with Type 2 diabetes, the bi-weekly GLP-1 receptor agonist GZR18 injection showed superior efficacy in lowering HbA1c and body weight compared to semaglutide (Ozempic ® ). |
| 2024-08-29 | Lexaria Bioscience Corp. | Results Lexaria's Second GLP-1 Human Pilot Study Shows Zero Adverse Events in DehydraTECH-processed Rybelsus® Oral Capsules lexariabioscience.com ↗
Lexaria’s DehydraTECH-processed Rybelsus ® capsules demonstrated superior tolerability in delivering the GLP-1 drug semaglutide versus commercially available Rybelsus ® . |
| 2024-08-27 | Lexaria Bioscience Corp. | Results First Results from Lexaria's Second GLP-1 Human Pilot Study lexariabioscience.com ↗ |
| 2024-08-22 | Lexaria Bioscience Corp. | Results Positive 8-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study lexariabioscience.com ↗
DehydraTECH-liraglutide is outperforming DehydraTECH-semaglutide |
| 2024-08-21 | Lexaria Bioscience Corp. | Results Positive Interim Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study lexariabioscience.com ↗
Interestingly, none of the animals receiving semaglutide experienced actual decreases by day 56 although some decreases were observed at day 28. |
| 2024-08-19 | Lexaria Bioscience Corp. | Results Positive Results from Lexaria's Molecular Characterization Study lexariabioscience.com ↗
Monomeric form of GLP-1 drug preserved by DehydraTECH |
| 2024-07-25 | Novo Nordisk A/S | Regulatory European regulatory authority adopts a positive opinion for an update of the Wegovy® label to reflect risk reduction of major adverse cardiovascular events novonordisk.com ↗ |
| 2024-07-17 | Lexaria Bioscience Corp. | Results Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study lexariabioscience.com ↗
DehydraTECH appears to be working with semaglutide both with and without SNAC technology |
| 2024-03-08 | Novo Nordisk A/S | Regulatory Wegovy® approved in the US for cardiovascular risk reduction in people with overweight or obesity and established cardiovascular disease novonordisk.com ↗ |
| 2024-03-05 | Novo Nordisk A/S | Results Novo Nordisk A/S: Semaglutide 1.0 mg demonstrates 24% reduction in the risk of kidney disease-related events in people with type 2 diabetes and chronic kidney disease in the FLOW trial novonordisk.com ↗
The trial achieved its primary endpoint by demonstrating a statistically significant and superior reduction in kidney disease progression as well as cardiovascular and kidney death of 24% for people treated with semaglutide 1.0 mg compared to placebo1. |
| 2024-01-04 | Lexaria Bioscience Corp. | Results Lexaria's Patented Technology Improved the Oral Performance of the Rybelsus®-Branded GLP-1 drug Semaglutide lexariabioscience.com ↗
Final results from a human pilot study show DehydraTECH TM -powered semaglutide outperforms Rybelsus ® : Sustained higher levels of semaglutide in blood; Better blood glucose control; Faster achievement of peak drug delivery; and Reduced side effects. |
| 2023-11-28 | Lexaria Bioscience Corp. | Results Lexaria's Technology Lowers Blood Glucose More Effectively than Rybelsus®-Branded GLP-1 drug Semaglutide Alone in Human Pilot Study lexariabioscience.com ↗ |
| 2023-11-27 | Lexaria Bioscience Corp. | Results Lexaria's Technology Improves the Oral Performance of the Rybelsus®-Branded GLP-1 drug Semaglutide in Human Pilot Study lexariabioscience.com ↗
The first post-baseline blood was sampled 20 minutes after oral administration and, at that point in time, the DehydraTECH GLP-1 blood semaglutide level was ~125% higher than that of the Control. |
| 2023-10-10 | Novo Nordisk A/S | Results Novo Nordisk will stop the once-weekly injectable semaglutide kidney outcomes trial, FLOW, based on interim analysis novonordisk.com ↗
The decision to stop the trial is based on a recommendation from the independent Data Monitoring Committee (DMC) concluding that the results from an interim analysis met certain pre-specified criteria for stopping the trial early for efficacy. |
| 2023-08-08 | Novo Nordisk A/S | Results Novo Nordisk A/S: Semaglutide 2.4 mg reduces the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity in the SELECT trial novonordisk.com ↗
The trial achieved its primary objective by demonstrating a statistically significant and superior reduction in MACE of 20% for people treated with semaglutide 2.4 mg compared to placebo1. |
| 2023-05-22 | Novo Nordisk A/S | Results Novo Nordisk A/S: Oral semaglutide 50 mg achieved 15.1% weight loss (17.4% if all people adhered to treatment) in adults with obesity or overweight in the OASIS 1 trial novonordisk.com ↗
The trial achieved its primary endpoint by demonstrating a statistically significant and superior weight loss at week 68 with oral semaglutide 50 mg versus placebo. |
| 2023-03-24 | Novo Nordisk A/S | Results Oral semaglutide 25 mg and 50 mg demonstrate superior reductions in HbA1c and body weight versus 14 mg in people with type 2 diabetes in the PIONEER PLUS phase 3 trial novonordisk.com ↗
The trial achieved its primary endpoint by demonstrating a statistically significant and superior reduction in HbA1c at week 52 with both the 25 mg and 50 mg doses versus the 14 mg dose of oral semaglutide. |
| 2022-08-22 | Novo Nordisk A/S | Results Novo Nordisk successfully completes phase 2 trial with CagriSema in people with type 2 diabetes novonordisk.com ↗
After 32 weeks of treatment, people treated with CagriSema achieved a numerically higher HbA1c reduction of 2.18%-points compared to a reduction of 1.79%-points for people treated with semaglutide and 0.93%-points with cagrilintide alone. |
| 2022-06-06 | Eli Lilly and Company | Results New analyses of Mounjaro™ (tirzepatide) injection for the treatment of adults with type 2 diabetes presented at the American Diabetes Association's® 82nd Scientific Sessions® lilly.com ↗
Exploratory analysis showed that Mounjaro achieved A1C and weight targets in less time than injectable semaglutide 1 mg or titrated insulin degludec |
| 2022-03-28 | Novo Nordisk A/S | Regulatory Ozempic® 2.0 mg approved in the US for the treatment of type 2 diabetes novonordisk.com ↗
Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved a 2.0 mg dose of Ozempic® (once-weekly semaglutide subcutaneous injection), a glucagon-like peptide-1 (GLP-1) analogue for the treatment of adults with type 2 diabetes. |
| 2021-11-12 | Novo Nordisk A/S | Regulatory Ozempic® 2.0 mg recommended for approval for the treatment of type 2 diabetes by the European Medicines Agency novonordisk.com ↗ |
| 2021-11-11 | Novo Nordisk A/S | Regulatory Wegovy™ recommended for approval for the treatment of obesity by the European regulatory authorities novonordisk.com ↗
Novo Nordisk today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending marketing authorisation for Wegovy™ for chronic weight management in adults with obesity. |
| 2021-06-25 | Eli Lilly and Company | Results Lilly's SURPASS-2 results published in The New England Journal of Medicine show tirzepatide achieved superior A1C and body weight reductions compared to injectable semaglutide in adults with type 2 diabetes lilly.com ↗
These results, which will also be featured during an ADA-sponsored symposium on Tuesday, June 29, showed that all three tirzepatide doses achieved greater A1C and weight reductions compared to semaglutide. |
| 2021-06-21 | Gilead Sciences | Results Gilead to Present More Than 70 Abstracts From Diverse Liver Disease Programs At The International Liver Congress™ 2021 gilead.com ↗
Combination treatments including semaglutide, cilofexor, and/or firsocostat lead to greater improvements in the FibroScan-AST (FAST) score compared to semaglutide alone in patients with non-alcoholic steatohepatitis |
| 2021-06-04 | Novo Nordisk A/S | Regulatory Wegovy™ (semaglutide 2.4 mg), the first and only once-weekly GLP-1 therapy for weight management, approved in the US novonordisk.com ↗
Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Wegovy™ (the brand name for once-weekly semaglutide 2.4 mg injection in the US) for chronic weight management. |
| 2021-05-28 | Novo Nordisk A/S | Regulatory Novo Nordisk resubmits once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes for US regulatory approval novonordisk.com ↗
Novo Nordisk today announced the resubmission of a label expansion application to the US Food and Drug Administration (FDA) for the existing marketing authorisation for Ozempic®, a once-weekly glucagon-like peptide-1 (GLP-1) analogue, to introduce a new dose of 2.0 mg. |
| 2021-03-22 | Novo Nordisk A/S | Regulatory Novo Nordisk receives Refusal to File letter for once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes novonordisk.com ↗
Novo Nordisk today announced that the US Food and Drug Administration (FDA) has issued a Refusal to File letter covering the label expansion application for once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes which was filed on 20 January 2021. |
| 2021-03-04 | Eli Lilly and Company | Results Tirzepatide achieved superior A1C and body weight reductions across all three doses compared to injectable semaglutide in adults with type 2 diabetes lilly.com ↗
Tirzepatide led to superior A1C and body weight reductions from baseline across all three doses compared to injectable semaglutide 1 mg in adults with type 2 diabetes in Eli Lilly and Company's (NYSE: LLY) 40-week SURPASS-2 clinical trial. |
| 2021-01-20 | Novo Nordisk A/S | Regulatory Novo Nordisk files for regulatory approval in the US of once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes novonordisk.com ↗
Novo Nordisk today announced the submission of a label expansion application to the US Food and Drug Administration (FDA) for the existing marketing authorisation for Ozempic®, a once-weekly glucagon-like peptide-1 (GLP-1) analogue, to introduce a new dose of 2.0 mg. |
| 2020-12-29 | Novo Nordisk A/S | Regulatory Novo Nordisk files for EU regulatory approval of once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes novonordisk.com ↗
Novo Nordisk today announced the submission of a label extension application to the European Medicines Agency (EMA) for the existing marketing authorisation for Ozempic®, a once-weekly glucagon-like peptide-1 (GLP-1) analogue, to introduce a new dose of 2.0 mg. |
| 2020-12-18 | Novo Nordisk A/S | Regulatory Novo Nordisk files for EU regulatory approval of once-weekly semaglutide 2.4 mg for weight management novonordisk.com ↗
Novo Nordisk today announced the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for subcutaneous semaglutide 2.4 mg, a once-weekly glucagon-like peptide-1 (GLP-1) analogue for weight management. |
| 2020-12-04 | Novo Nordisk A/S | Regulatory Novo Nordisk files for US FDA regulatory approval of once-weekly semaglutide 2.4 mg for weight management novonordisk.com ↗
Novo Nordisk today announced the submission of a new drug application (NDA) to the US Food and Drug Administration (FDA) for subcutaneous semaglutide 2.4 mg, a once-weekly glucagon-like peptide-1 (GLP-1) analogue for chronic weight management. |
| 2020-11-17 | Novo Nordisk A/S | Results Once-weekly semaglutide 2.0 mg demonstrates superior reduction in HbA1c vs once-weekly semaglutide 1.0 mg in people with type 2 diabetes in the SUSTAIN FORTE trial novonordisk.com ↗
The trial achieved its primary endpoint by demonstrating a statistically significant and superior reduction in HbA1c at week 40 with semaglutide 2.0 mg compared to semaglutide 1.0 mg. |
| 2020-11-15 | Novo Nordisk A/S | Results Gilead and Novo Nordisk present new data from proof-of-concept trial in NASH novonordisk.com ↗
The trial met its primary endpoint by demonstrating that in people with NASH and mild to moderate fibrosis all regimens were well tolerated. |
| 2020-11-15 | Gilead Sciences | Results Gilead and Novo Nordisk Present New Data from Proof-of-Concept Trial in NASH gilead.com ↗
The trial met its primary endpoint by demonstrating that in people with NASH and mild to moderate fibrosis all regimens were well tolerated. |
| 2020-06-29 | Novo Nordisk A/S | Regulatory Rybelsus® approved in Japan for the treatment of type 2 diabetes novonordisk.com ↗ |
| 2020-06-18 | Novo Nordisk A/S | Results Novo Nordisk successfully completes AM833 phase 2 trial and phase 1 combination trial with AM833 and semaglutide in obesity novonordisk.com ↗
After 20 weeks of treatment, participants receiving the highest dose lost an average of 17.1% body weight from a mean baseline body weight of 95.1 kg (secondary end-point)1. |
| 2020-06-13 | Eli Lilly and Company | Results Once-weekly Trulicity® (dulaglutide) demonstrates significantly higher adherence and more persistence compared to once-weekly semaglutide and exenatide injections lilly.com ↗
New real-world data showed Trulicity® (dulaglutide) had significantly higher adherence and longer persistence compared to weekly injections of semaglutide or exenatide (BCise pen) in people with type 2 diabetes new to GLP-1 receptor agonist (RA) treatment. |
| 2020-06-12 | Novo Nordisk A/S | Results Semaglutide 2.4 mg shows superior weight loss versus placebo in the phase 3 trials STEP 2 and STEP 3, thereby successfully completing the programme novonordisk.com ↗
Novo Nordisk today announced headline results from the final two phase 3a clinical trials investigating once-weekly subcutaneous (sc) semaglutide 2.4 mg for weight management. |
| 2020-06-04 | Novo Nordisk A/S | Results Novo Nordisk reports weight loss of 14.9% (16.9% if taken as intended) in STEP 1 trial novonordisk.com ↗
People treated with sc semaglutide 2.4 mg achieved a weight loss of 14.9%, from a mean baseline body weight of 105.3 kg, compared to a 2.4% weight loss with placebo. |
| 2020-05-13 | Novo Nordisk A/S | Results Semaglutide 2.4 mg demonstrates superior and sustained weight loss versus placebo and in addition a 17.4% weight loss after 68 weeks in STEP 4 trial novonordisk.com ↗
Novo Nordisk today announced headline results from STEP 4, the first completed phase 3a trial in the STEP programme. |
| 2020-04-04 | Novo Nordisk A/S | Regulatory Rybelsus® (oral semaglutide) approved for the treatment of adults with type 2 diabetes in the EU novonordisk.com ↗
Novo Nordisk today announced that the European Commission (EC) has granted marketing authorisation for Rybelsus® (oral semaglutide), for the treatment of adults with insufficiently controlled type 2 diabetes to improve glycaemic control as an adjunct to diet and exercise. |
| 2020-01-31 | Novo Nordisk A/S | Regulatory Rybelsus® (oral semaglutide) recommended for approval for the treatment of adults with type 2 diabetes by the European regulatory authorities novonordisk.com ↗
The CHMP recommends Rybelsus® to be indicated as monotherapy when metformin is considered inappropriate, as well as in combination with other medicinal products for the treatment of type 2 diabetes. |
| 2020-01-16 | Novo Nordisk A/S | Regulatory Ozempic® approved in the US for CV risk reduction in people with type 2 diabetes and established CVD novonordisk.com ↗
Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved a label expansion based on a supplemental New Drug Application (sNDA) for Ozempic® (once-weekly semaglutide) for the indication of reducing the risk of major adverse cardiovascular events (MACE) including cardiovascular death, non-fatal heart attack, or non-fatal stroke in adults with type 2 diabetes and established cardiovascular disease (CVD). |
| 2019-09-20 | Novo Nordisk A/S | Regulatory Rybelsus® (semaglutide tablets), the first GLP-1 in a tablet approved in the US novonordisk.com ↗
Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Rybelsus® (semaglutide tablets), as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus. |
| 2019-04-26 | Novo Nordisk A/S | Regulatory Novo Nordisk files for EU regulatory approval of oral semaglutide for the treatment of type 2 diabetes novonordisk.com ↗
Novo Nordisk today announced the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for oral semaglutide, a glucagon-like peptide-1 (GLP-1) analogue in a tablet taken once-daily, for the treatment of adults with type 2 diabetes. |
| 2019-03-20 | Novo Nordisk A/S | Regulatory Novo Nordisk files oral semaglutide for US regulatory approval of glycaemic control, as well as for CV risk reduction for oral semaglutide and Ozempic® novonordisk.com ↗
An NDA was submitted for oral semaglutide seeking approval for an indication for the treatment of adults with type 2 diabetes. |
| 2018-11-23 | Novo Nordisk A/S | Results Oral semaglutid viser en positiv kardiovaskulær sikkerhedsprofil og en signifikant reduktion i hjerte-kar-dødsfald og den samlede dødelighed hos mennesker med type 2-diabetes i PIONEER 6-studiet novonordisk.com ↗
Studiet opfyldte sit primære mål, idet det viste ikke-inferiøritet med hensyn til alvorlige kardiovaskulære hændelser for oral semaglutid sammenlignet med placebo, begge givet som supplement til standardbehandling. |
| 2018-11-23 | Novo Nordisk A/S | Results Oral semaglutide demonstrates favourable cardiovascular safety profile and significant reduction in cardiovascular death and all-cause mortality in people with type 2 diabetes in the PIONEER 6 trial novonordisk.com ↗
The trial achieved its primary endpoint by demonstrating non-inferiority of major adverse cardiovascular events (MACE) with oral semaglutide compared with placebo, both in addition to standard of care. |
| 2018-11-22 | Novo Nordisk A/S | Results Oral semaglutide demonstrates greater reductions in both HbA1c and body weight compared to Victoza® in Japanese people with type 2 diabetes novonordisk.com ↗
Furthermore, 14 mg oral semaglutide achieved a statistically significantly greater reduction in HbA1c compared to a reduction of 1.4% with Victoza®. |
| 2018-10-26 | Novo Nordisk A/S | Results Oral semaglutide demonstrates statistically significant reductions in HbA1c and body weight in people with long duration of type 2 diabetes treated with insulin novonordisk.com ↗
Novo Nordisk today announced the headline results from PIONEER 8, a phase 3a trial with oral semaglutide for the treatment of adults with type 2 diabetes. |
| 2018-09-20 | Novo Nordisk A/S | Results Novo Nordisk - Oral semaglutide demonstrates greater reductions in HbA1c and body weight and comparable number of adverse events vs dulaglutide in Japanese people with type 2 diabetes novonordisk.com ↗
Novo Nordisk today announced the headline results from PIONEER 10, a phase 3a trial with oral semaglutide vs once-weekly subcutaneous dulaglutide, both in combination with one oral antidiabetic drug in Japanese adults with type 2 diabetes. |
| 2018-06-28 | Novo Nordisk A/S | Results Oral semaglutide shows superior reductions in HbA1c and weight compared to sitagliptin in the long-term safety and efficacy trial, PIONEER 3 novonordisk.com ↗
The trial achieved its primary objective according to the primary statistical approach by demonstrating statistically significant and superior reductions in HbA1c with oral semaglutide 7 and 14 mg compared to sitagliptin at week 26. |
| 2018-06-20 | Novo Nordisk A/S | Results Oral semaglutide shows statistically significantly greater reductions in HbA1c and weight compared to Victoza® and sitagliptin in the PIONEER 4 and 7 trials novonordisk.com ↗
PIONEER 4 achieved its primary objective according to the primary statistical approach by demonstrating a non-inferior reduction in HbA1c and statistically significant and superior weight loss at 26 weeks with oral semaglutide compared to Victoza®. |
| 2018-05-29 | Novo Nordisk A/S | Results Oral semaglutide shows superior improvement in HbA1c vs empagliflozin in the PIONEER 2 trial novonordisk.com ↗
The trial achieved its primary objective according to the primary statistical approach by demonstrating a statistically significant and superior improvement in HbA1c with oral semaglutide compared to empagliflozin at 26 weeks. |
| 2018-03-23 | Novo Nordisk A/S | Regulatory Ozempic® godkendt i Japan til behandling af type 2-diabetes novonordisk.com ↗ |
| 2018-03-23 | Novo Nordisk A/S | Regulatory Ozempic® approved in Japan for the treatment of type 2 diabetes novonordisk.com ↗
Novo Nordisk today announced that the Japanese Ministry of Health, Labour and Welfare has approved Ozempic® (semaglutide), a new once-weekly analogue of human glucagon-like peptide-1 (GLP-1), for the treatment of adults with type 2 diabetes. |
| 2018-02-22 | Novo Nordisk A/S | Results Novo Nordisk successfully completes the first phase 3a trial, PIONEER 1, with oral semaglutide novonordisk.com ↗
Novo Nordisk today announced the headline results from PIONEER 1, the first phase 3a trial with oral semaglutide for treatment of adults with type 2 diabetes. |
| 2018-02-09 | Novo Nordisk A/S | Regulatory Novo Nordisk A/S: Ozempic® (semaglutid) godkendt i EU til behandling af type 2-diabetes novonordisk.com ↗
Bagsværd, den 9. februar 2018 - Novo Nordisk meddeler i dag, at Europa-Kommissionen har givet markedsføringstilladelse til Ozempic® (semaglutid) til behandling af voksne med type 2-diabetes. |
| 2018-02-09 | Novo Nordisk A/S | Regulatory Novo Nordisk A/S: Ozempic® (semaglutide) approved in the EU for the treatment of type 2 diabetes novonordisk.com ↗
Novo Nordisk today announced that the European Commission (EC) has granted marketing authorisation for Ozempic® (semaglutide) for the treatment of adults with type 2 diabetes. |
| 2017-12-15 | Novo Nordisk A/S | Regulatory Ozempic® (semaglutid) får anbefaling om godkendelse fra de europæiske lægemiddelmyndigheder novonordisk.com ↗
Bagsværd, den 15. december 2017 - Novo Nordisk meddeler i dag, at Udvalget for Humanmedicinske Lægemidler (CHMP) under Det Europæiske Lægemiddelagentur (EMA) har afgivet en positiv udtalelse om Ozempic® (semaglutid) med anbefaling om markedsføringstilladelse til behandling af voksne med type 2-diabetes. |
| 2017-12-15 | Novo Nordisk A/S | Regulatory Ozempic® (semaglutide) recommended for approval by the European regulatory authorities novonordisk.com ↗
The CHMP recommends Ozempic®, the intended brand name for once-weekly semaglutide, to be indicated as monotherapy when metformin no longer provides sufficient treatment or is contraindicated and as an addition to other medicinal products for the treatment of diabetes. |
| 2017-12-05 | Novo Nordisk A/S | Regulatory Ozempic® (semaglutid) godkendt i USA novonordisk.com ↗
Novo Nordisk meddeler i dag, at de amerikanske sundhedsmyndigheder, FDA, har godkendt Ozempic® (semaglutid i injektionsform). |
| 2017-12-05 | Novo Nordisk A/S | Regulatory Ozempic® (semaglutide) approved in the US novonordisk.com ↗
Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Ozempic® (semaglutide injection). |
| 2017-10-18 | Novo Nordisk A/S | Regulatory Semaglutide receives positive 16-0 vote in favour of approval from FDA Advisory Committee novonordisk.com ↗
Novo Nordisk today announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the US Food and Drug Administration (FDA) voted 16-0 in favour of the approval of once-weekly semaglutide to improve glycaemic control in adults with type 2 diabetes. |
| 2017-08-16 | Novo Nordisk A/S | Results Semaglutide superior to dulaglutide on glucose control and weight loss in people with type 2 diabetes in SUSTAIN 7 novonordisk.com ↗
Novo Nordisk today announced the SUSTAIN 7 trial results, demonstrating that people with type 2 diabetes treated with once-weekly semaglutide experienced superior reduction in HbA1c and body weight compared to treatment with dulaglutide. |
| 2017-08-16 | Novo Nordisk A/S | Results Semaglutid viser superioritet sammenlignet med dulaglutid med hensyn til blodsukkerkontrol og vægttab hos mennesker med type 2-diabetes i SUSTAIN 7 novonordisk.com ↗
Deltagere, der blev behandlet med 1,0 mg semaglutid, opnåede en statistisk signifikant og superiør reduktion på 1,8% mod en reduktion på 1,4% med 1,5 mg dulaglutid. |
| 2017-06-23 | Novo Nordisk A/S | Results Novo Nordisk reports up to 13.8% weight loss in people with obesity receiving semaglutide in phase 2 trial novonordisk.com ↗
This corresponded to an estimated 13.8% weight loss compared to the weight loss of 2.3% achieved by diet, exercise and placebo alone, with all treatment arms adjusted for people discontinuing treatment in the study. |
| 2017-02-28 | Novo Nordisk A/S | Regulatory Novo Nordisk files for regulatory approval of once-weekly semaglutide for the treatment of type 2 diabetes in Japan novonordisk.com ↗
Novo Nordisk today announced the submission of a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare for semaglutide, a new glucagon-like peptide-1 (GLP-1) analogue administrated once-weekly, for the treatment of adults with type 2 diabetes. |
| 2016-12-05 | Novo Nordisk A/S | Regulatory Novo Nordisk files for regulatory approval of once-weekly semaglutide in the US and EU for the treatment of type 2 diabetes novonordisk.com ↗ |
| 2016-04-28 | Novo Nordisk A/S | Results Semaglutide significantly reduces the risk of major adverse cardiovascular events in the SUSTAIN 6 trial novonordisk.com ↗
The trial achieved its primary endpoint of showing non-inferiority of major cardiovascular events (MACE) with semaglutide compared with placebo, as well as a statistically significant reduction in cardiovascular risk. |
| 2016-02-23 | Novo Nordisk A/S | Results Novo Nordisk successfully completes fifth phase 3a trial with semaglutide in people with type 2 diabetes novonordisk.com ↗
Novo Nordisk today announced the headline results from the fifth phase 3a trial for semaglutide, SUSTAIN5. |
| 2015-12-17 | Novo Nordisk A/S | Results Novo Nordisk successfully completes fourth phase 3a trial with semaglutide in people with type 2 diabetes novonordisk.com ↗
Novo Nordisk today announced the headline results from the fourth phase 3a trial for semaglutide, SUSTAIN2. |
| 2015-11-18 | Novo Nordisk A/S | Results Highlights to be presented at Novo Nordisk's Capital Markets Day 2015 novonordisk.com ↗
SUSTAIN 4, the third phase 3a trial for semaglutide to report results, included a total of 1,089 people with type 2 diabetes previously treated with metformin with or without sulfonylurea. |
| 2015-09-25 | Novo Nordisk A/S | Results Novo Nordisk successfully completes second phase 3a trial with semaglutide in people with type 2 diabetes novonordisk.com ↗
Novo Nordisk today announced the headline results from the second phase 3a trial for semaglutide, SUSTAIN3. |
| 2015-07-10 | Novo Nordisk A/S | Results Novo Nordisk successfully completes first phase 3a trial with semaglutide in people with type 2 diabetes novonordisk.com ↗
Novo Nordisk today announced the headline results from SUSTAIN1, the first phase 3a trial for semaglutide, a new GLP-1 analogue administered once-weekly. |
| 2015-02-20 | Novo Nordisk A/S | Results Novo Nordisk announces positive results for phase 2 trial with oral semaglutide in people with type 2 diabetes novonordisk.com ↗ |
All press releases naming this drug 210 releases
| Date | Issuer | Release |
|---|---|---|
| Show all 210 releases opens the full record — a long page | ||
Evidence & citations 24 cited values
Every value below carries the sentence it was read from. 566 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | semaglutide | “Subjects will receive a glucagon-like peptide 1 receptor agonist (either semaglutide, tirzepatide or liraglutide) by self-injection or orally (semaglutide or orforglipron) for...” NCT07107334 ↗550“Weekly subcutaneous semaglutide/GLP-1 receptor agonist therapy administered according to approved labeling, clinical indication, patient tolerance, and endocrinology...” NCT07462663 ↗ “Receive 6 months of GLP-1RA (Semaglutide) treatment starting at 0.25mg once weekly and then the dose will be up titrated as tolerated every four weeks to once-weekly doses of...” NCT07178145 ↗ “BACKGROUND: Oral semaglutide is a novel tablet containing the human glucagon-like peptide-1 (GLP‑1) analogue semaglutide, co-formulated with the absorption enhancer sodium...” PMID 30565096 ↗ Jun 2019 “Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is an approved and well-established therapy for type 2 diabetes mellitus (T2DM), providing both robust glycemic...” NCT07563699 ↗ “Safety And Tolerability of 3 Switch Regimens From Semaglutide 1.0 mg and 2.0 mg to Co-Administered Cagrilintide and Semaglutide (Cagrisema) in Participants With Type 2 Diabetes” NCT07817251 ↗ “Three incretin-based medications that have been approved for treatment of obesity including liraglutide, semaglutide, or tirzepatide will be used in the nonsurgical group.” NCT06374875 ↗ “Key question: Is the use of GLP-1 weight loss medicines - semaglutide and tirzepatide - associated with improvements in mental health and health-related quality of life?” NCT07368855 ↗ “IcoSema is a once-weekly combination therapy of basal insulin icodec (icodec) and semaglutide (a GLP-1 analogue) developed for the treatment of type 2 diabetes.” PMID 40482670 ↗ Jun 2025 “Wegovy®: Semaglutide injected once weekly, starting dose 0.25mg, with dose increments every four weeks reaching the maintenance dose of 1mg after eight weeks” NCT06715514 ↗ “The glucagon-like peptide-1 receptor agonist semaglutide is approved for the treatment of type 2 diabetes and obesity and has an established safety profile.” PMID 39780249 ↗ Jan 2025 |
| Known as | Fitaro | “In Bangladesh, semaglutide (Fitaro) is available for weight management at various doses (0.25 mg to 2.4 mg)” NCT06616961 ↗ |
| Known as | NN-9535 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108724 ↗ |
| Known as | NNC0113-0217 | “Investigation of Pharmacokinetics, Safety and Tolerability of Oral Semaglutide (NNC0113-0217)” NCT02016911 ↗1“oral semaglutide (NNC0113-0217)” NCT02070510 ↗ |
| Known as | NPM-139 | “Semaglutide Implant (NPM-139) is a drug/device combination product consisting of a subdermal titanium implant \~23 mm long and 2 mm in diameter, containing a sterile liquid...” NCT07430059 ↗ |
| Known as | Ozempic | “If possible, patients will be placed on high-dose tirzepatide (Mounjaro or Zepbound 15 mg once weekly injection) or high-dose semaglutide (Wegovy 2.4 mg once weekly injection...” NCT06374875 ↗26“Such an approach is now in particular of relevance, since the European Medicines Agency (EMA) has already approved semaglutide s.c. (Ozempic) and semaglutide in an oral formula...” NCT05303857 ↗ “Semaglutide is already approved in several formulations (examples: Ozempic® for type 2 diabetes and Wegovy® for weight management), but these require once-weekly injections.” NCT07563699 ↗ “GLP-1 medications such as semaglutide (e.g. Ozempic) are approved for diabetes and medication, and may potentially affect craving for other substances apart from food.” NCT07509112 ↗ “Semaglutide is a glucagon-like peptide 1 receptor agonist (GLP-1 RA) that is FDA-approved for the treatment of obesity (as Wegovy) or T2DM (as Ozempic).” NCT06005012 ↗ “New medicines called GLP-1 receptor agonists, like semaglutide (Ozempic) and tirzepatide (Mounjaro), help people lose weight and improve health.” NCT07179120 ↗ “Upon introduction of semaglutide (ozempic) treatment, insulin doses will be reduced by 10% (basal insulin, basal rate and bolus)” NCT05305794 ↗ “combined with a GLP-1 receptor agonist (Semaglutide, Ozempic) in subjects with insulin-dependent type 2 diabetes mellitus.” NCT05984238 ↗ “The Effect of Semaglutide (Ozempic) on Bone Turnover in Patients With Increased Fracture Risk” NCT04702516 ↗ “Semaglutide, Ozempic® (at maximum tolerated dose) + Automated Insulin Delivery system” NCT06894784 ↗ “Weekly semaglutide (Ozempic®) injections on regular closed-loop insulin pump therapy” NCT06387199 ↗ |
| Known as | Ozempyc | “Subcutaneous semaglutide (Ozempyc, Novo Nordisk A/S Bagsvaerd, Denmark)” NCT06541509 ↗ |
| Known as | Rybelsus | “Such an approach is now in particular of relevance, since the European Medicines Agency (EMA) has already approved semaglutide s.c. (Ozempic) and semaglutide in an oral formula...” NCT05303857 ↗24“Once daily semaglutide tablets (3 mg, 7 mg and 14 mg) are approved for the treatment of type 2 diabetes in the US, in the EU and in some other countries, under the brand name Rybelsus®.” NCT04707469 ↗ “Other acceptable, less preferrable, options: liraglutide (Saxenda or Victoza), semaglutide tablet (Rybelsus), or lower dose of tirzepatide and semaglutide injections.” NCT06374875 ↗ “Oral semaglutide (Rybelsus®) was purchased and then repackaged into capsules looking identical to DGE, CQE and placebo capsules.” NCT06827002 ↗ “Currently, doses of 3 milligram (mg), 7 mg and 14 mg semaglutide tablets (Rybelsus) can be prescribed in some countries.” NCT06083675 ↗ “Semaglutide tablets, under the brand name Rybelsus, are approved in the EU and USA for the treatment of type 2 diabetes.” NCT05996874 ↗ “semaglutide (Rybelsus®) 3 mg daily for 4 weeks followed by 7 mg daily for 4 weeks, hereafter 14 mg daily” NCT07135245 ↗ “Participants receive 7mg of semaglutide (Rybelsus®) orally once before one of the post-TZIELD® MMTTs.” NCT06338553 ↗ “semaglutide/Rybelsus will be administered as a single oral dose” NCT06608433 ↗ “Arm 4 - Rybelsus medication (semaglutide) alone” NCT06648031 ↗ “called oral semaglutide (Rybelsus)” NCT06003153 ↗ |
| Known as | SEMA | “randomised to semaglutide (SEMA) 1 mg/week or intramuscular testosterone undecanoate (TRT) 1000 mg/10-12 weeks for 24 weeks” PMID 39511836 ↗ Nov 20243“Drug: Semaglutide (SEMA)” NCT07586150 ↗ “Semaglutide (SEMA)” NCT07389941 ↗ “Semaglutide (SEMA)” NCT04971785 ↗ |
| Known as | Semagluide | “Semagluide” NCT07539415 ↗ |
| Known as | Semaglutida | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108724 ↗ |
| Known as | semaglutide (Ozempic) | “semaglutide (Ozempic)” NCT07325435 ↗ |
| Known as | Semaglutide component of cagrisema | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108724 ↗ |
| Known as | Semaglutide component of nn1535 icosema | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108724 ↗ |
| Known as | Semaglutide component of nn1535 laisema | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108724 ↗ |
| Known as | semaglutide I | “Participants will receive a single subcutaneous (s.c.) dose of CagriSema (cagrilintide B and semaglutide I) in DV3384 pen-injector in period 1 followed by a single s.c. dose of...” NCT06716307 ↗ |
| Known as | Semaglutide Injection | “Semaglutide Injection, 0.68 mg/mL，1.5 mL；1.34 mg/mL，1.5 mL；1.34 mg/mL，3 mL；2.27 mg/mL，3 mL；3.2 mg/mL，3 mL; Subcutaneous injection once weekly using pre-filled pen including...” NCT06863363 ↗ |
| Known as | Semaglutide Pen | “Drug: Semaglutide Pen” NCT06616961 ↗ |
| Known as | TQF3510 | “This is a multicenter, randomized, open, parallel, positive-controlled clinical study to evaluate the efficacy and safety of Semaglutide injection (TQF3510) developed by Chia...” NCT06738979 ↗ |
| Known as | Wegovy | “The intervention consists of once-weekly subcutaneous semaglutide (Wegovy®), initiated at 0.25 mg and uptitrated to a target dose of 2.4 mg as tolerated, administered for at...” NCT07275697 ↗27“The GLP-1 agonist class of drugs, including semaglutide (Wegovy®), have been approved for the treatment of patients as an adjunct to diet and exercise and for weight loss in...” NCT06754163 ↗ “If possible, patients will be placed on high-dose tirzepatide (Mounjaro or Zepbound 15 mg once weekly injection) or high-dose semaglutide (Wegovy 2.4 mg once weekly injection...” NCT06374875 ↗ “Semaglutide is already approved in several formulations (examples: Ozempic® for type 2 diabetes and Wegovy® for weight management), but these require once-weekly injections.” NCT07563699 ↗ “Wegovy®: Semaglutide injected once weekly, starting dose 0.25mg, with dose increments every four weeks reaching the maintenance dose of 1mg after eight weeks” NCT06715514 ↗ “Semaglutide is a glucagon-like peptide 1 receptor agonist (GLP-1 RA) that is FDA-approved for the treatment of obesity (as Wegovy) or T2DM (as Ozempic).” NCT06005012 ↗ “Semaglutide (Wegovy) is a clear, colorless solution provided as Wegovy FlexTouch four-dose pens: 0.25 mg/0.5 mL.” NCT07430059 ↗ “semaglutide (Wegovy) once-weekly by subcutaneous injection, titrated to a maximum dose of 2.4 mg.” NCT07523633 ↗ “semaglutide injection or WEGOVY® injection will be given once weekly” NCT07036172 ↗ “All participants in the study will receive semaglutide (Wegovy).” NCT07282769 ↗ “Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY]” NCT06913023 ↗ |
| Action | Activate | “GLP-1 receptor agonist drug class” PMID 30565096 ↗ Jun 2019 |
| Modality | Peptide | “Semaglutide, a Human Glucagon-Like Peptide-1 Analog” PMID 28349386 ↗ Nov 2017 |
| Route | Subcutaneous | “subcutaneous injection of semaglutide once weekly” PMID 26358288 ↗ Sep 2015 |
| Target | GLP1R | “a glucagon-like peptide-1 (GLP-1) receptor agonist” PMID 31189520 ↗ Jun 2019 |